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Advances in screening and treatment strategies have led to a growing population of long-term 
breast cancer survivors in the United States. Although studies in breast cancer survivors have 
reported bone loss, cardiovascular disease (CVD), and trends in mortality, the additional effect of 
cancer and its treatment on these outcomes is unclear due to limited comparisons with cancer-free 
women. The aim of this dissertation was to evaluate the risk of bone loss, CVD, and mortality in 
breast cancer survivors relative to a cancer-free comparison within the same cohort. 
 
First, we prospectively examined all-cause and CVD-related mortality in breast cancer survivors 
relative to cancer-free women in a community-based cohort. We found that survivors, irrespective 
of stage, estrogen-receptor (ER)-status, and time since diagnosis, had a higher risk of all-cause 
mortality compared to cancer-free women. We further observed an increase in all-cause mortality 
over time among survivors diagnosed at age ≥70. Survivors had higher CVD-related mortality 
after 8 years, particularly among those diagnosed at age ≥70 and those with ER-positive tumors, 
compared to cancer-free women. 
 
Second, we examined incident CVD risk factors shortly after diagnosis in breast cancer survivors 
compared to cancer-free women within a familial risk cohort. Overall, survivors did not have a 
higher risk of hypertension, high cholesterol, or diabetes compared to cancer-free women. 
However, compared to cancer-free women, survivors had an increased risk of high triglycerides 
and survivors diagnosed at age ≤50 years had an increased risk of hypertension.  
 
 iii 
Third, we prospectively evaluated bone loss in breast cancer survivors compared to cancer-free 
women within a familial risk cohort. We found an overall increased risk of bone loss in survivors 
compared to cancer-free women. Risk of bone loss was higher among women diagnosed at age 
≤50 years, women with ER-positive tumors, and women treated with aromatase inhibitors alone 
or chemotherapy plus any hormonal therapy. 
 
Overall, this dissertation informs and improves our understanding of breast cancer and its related 
treatment on bone loss, CVD, and mortality. Results support a more tailored approach to 
treatment and prevention strategies, and further evaluation of these interventions to improve the 
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This dissertation examines both short- and long-term adverse health outcomes among breast 
cancer survivors compared to cancer-free women. Observational and clinical studies have 
reported that breast cancer survivors have an increased risk of bone loss, cardiovascular disease 
(CVD), and overall mortality. However, it is unclear if these adverse outcomes are primarily due 
to the effects of breast cancer and its treatment or may be driven, in part, by age, menopause, and 
lifestyle factors. Thus, the overarching aim of this dissertation is to determine whether the risk of 
these adverse outcomes is higher in breast cancer survivors relative to cancer-free women of 
similar age.  
 
This dissertation aims to address the following questions: Are breast cancer survivors at increased 
risk for long-term all-cause and CVD-related mortality compared to cancer-free women and does 
this risk vary by tumor characteristics, age at diagnosis, and time since diagnosis? Do breast 
cancer survivors have a higher risk of developing CVD risk factors shortly after diagnosis 
compared to their cancer-free peers? Are young women with breast cancer at increased risk for 
bone loss after diagnosis compared to cancer-free women?  
 
The answers to these questions will help inform additional health risks specific to survivors, 
which may be due to breast cancer and its treatment versus factors such as age, menopause, and 
lifestyle that apply to all women. This information can then be used to guide the evaluation of 
interventions to reduce the risk of bone loss and CVD as well as improve the long-term survival 




1-1. Breast cancer incidence 
 
In the United States, breast cancer is the most common cancer (excluding non-melanoma skin 
cancer) in females, accounting for approximately one in three cancers diagnosed among women.1 
In 2018, it is estimated that there will be over 266,000 incident cases of breast cancer.2 Trends in 
breast cancer incidence have changed over time. From 1980 to 2003, an increase in breast cancer 
incidence was observed due to the introduction and widespread use of mammography screening 
as well as changes in breast cancer risk factors including reproductive patterns (e.g., delayed 
childbirth and having fewer children), obesity, and menopausal hormone use.3 Despite a brief 
reduction in breast cancer incidence in the early 2000s,4-6 breast cancer incidence has remained 
stable over the past decade.7 
 
1-2. Breast cancer mortality 
 
Breast cancer is the second leading cause of cancer death in the United States with almost 41,000 
breast cancer deaths expected in 2018.2 Over time, breast cancer mortality rates have decreased 
largely due to advances in effective screening (e.g., early detection with mammography) and 
treatment strategies (e.g., adjuvant chemotherapy and hormonal therapy in the 1980s and targeted 
therapies in the 1990s).8,9 Overall, breast cancer mortality rates have decreased by 39% from 
1990 to 2015.3 As a result, an estimated 300,000 female breast cancer deaths in the United States 
have been averted through 2015, which has led to a growing population of breast cancer 
survivors.3 
 
1-3. Breast cancer survivors  
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Currently, there are over 8 million women living with a history of a cancer diagnosis in the 
United States.10 Among these women, breast cancer currently represents the largest group of 
survivors (44% of female survivors) due to the relatively high incidence and low mortality rates 
(Table 1-1).10,11 Breast cancer survivors are also living longer after their diagnosis, which is 
giving rising to an increasing number of long-term survivors at risk for adverse effects from their 
initial breast cancer diagnosis and its related treatment.11 
 
1-4. Definition of a breast cancer survivor 
 
The National Coalition for Cancer Survivorship (NCCS) and the National Cancer Institute define 
a cancer survivor as an individual diagnosed with cancer from the time of diagnosis until the end 
of life.12,13 Throughout this dissertation, “breast cancer survivor” will refer to a female with a 
breast cancer diagnosis regardless of time since diagnosis. Depending on our research question, 
we included women with in situ breast cancer in our definition of breast cancer survivor. 
 
1-5. Established prognostic factors for breast cancer survival 
 
Overall, 91% of women will survive 5 years or longer after a breast cancer diagnosis and 86% of 
women will survive 10 years or longer.7 However, survival rates vary by pathological features of 
the tumor (e.g., stage and subtype), as well as clinical (e.g., treatment) and patient characteristics 
(e.g., age, race). 
 
1-5a. Breast cancer stage  
 
Breast cancer stage is an important prognostic factor that describes the extent of cancer at 
diagnosis and guides treatment options. In the United States, breast cancer stage is commonly 
 5 
classified with either the TNM staging system or the summary stage system. This dissertation 
utilizes the TNM staging system, which is commonly used by clinicians, and incorporates 
information on tumor size (T), presence or absence of regional lymph node involvement (N), and 
presence or absence of distant metastasis (M).7 TNM staging categorizes breast cancer into stage 
0 for carcinoma in situ and stage I-IV for invasive breast cancer. Breast cancers up to stage III are 
considered early stage since cancer cells have not spread beyond the site of origin or axillary 
lymph nodes. Overall, breast cancer survival decreases with increasing stage. The five-year 
survival rate for women with localized disease is nearly 100% with 5-year survival rates 
decreasing for those with regional and distant stage disease to 85% and 27%, respectively.14 
Incident breast cancer cases are diagnosed primarily at the localized stage (62% of incident 
cases), therefore many women diagnosed with breast cancer will survive beyond five years after 
their diagnosis.14 
 
1-5b. Breast cancer subtype 
 
Breast cancer can be classified into several distinct molecular subtypes based on gene expression 
patterns (luminal A, luminal B, HER-2-enriched, and basal like).15 These molecular subtypes are 
defined by the joint expression of three tumor markers at diagnosis: estrogen receptors (ER), 
progesterone receptors (PR), and human epidermal growth factor receptor 2 (HER-2). 
Approximately 70% of breast tumors are hormone receptor (HR)-positive (ER and/or PR-
positive) and HER-2-negative (also known as Luminal A).16 This subtype has been associated 
with the most favorable prognosis with 5-year breast cancer specific survival rates at 96%.17,18 
HR-positive tumors can also overexpress HER-2 (Luminal B subtype) and represent 
approximately 10% of breast cancer tumors.16 In addition, approximately 5% of tumors are HR-
negative and HER-2-positive (HER-2 overexpressing subtype).16 HER-2-positive tumors are 
associated with slightly lower survival with 5-year breast cancer-specific survival estimates at 
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88% for HR-positive/HER-2-positive tumors and 81% for HR-negative/HER-2-positive tumors.18 
Finally, approximately 12% of breast tumors are classified as triple negative, which is defined as 
the absence of expression of ER, PR, and HER-2.16 Triple negative tumors are often classified 
into the molecular subtype of basal-like. At diagnosis, these tumors are commonly associated 
with advanced stage,19 higher grade,20 and younger age.21,22 Triple negative tumors also tend to 
occur more often in African-American women,19-22 women with BRCA1 mutations23 and women 
with a family history of cancer.24 Prognosis among triple negative breast cancers tends to be poor, 
largely due to limited treatment options.19    
 
1-5c. Breast cancer treatment 
 
Advancements in treatment strategies over time have improved breast cancer survival rates. 
Treatment regimes, which are largely dependent on breast cancer stage and subtype, include 
surgery (e.g., breast conserving surgery [lumpectomy, partial mastectomy] or total mastectomy), 
radiation therapy, chemotherapy, hormone therapy, and targeted therapies.25 Whether a patient 
receives systemic therapy (chemotherapy, hormone therapy, and targeted therapies) largely 
depends on the size of the tumor, lymph node involvement, and the presence of hormone 
receptors (ER/PR) and the HER-2 protein. Women with in situ cancer typically receive breast 
conserving surgery, but may also receive a combination of radiation and/or hormone therapy 
depending on their risk of recurrence or progression.3 Women with early stage invasive cancer 
usually receive surgery plus a combination of radiation, chemotherapy, hormone and/or targeted 
therapies. Women with stage IV breast cancer will primarily receive systemic treatment.3  
 
Radiation therapy is often used after surgery to eliminate any remaining cancer cells locally. 
External beam radiation therapy is considered the standard method with a typical course 
occurring 5 days per week for 5-7 weeks.3 Overall, radiation has been shown to reduce local and 
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regional recurrence and breast cancer death rates.26,27 Among women with breast conserving 
therapy, radiation has been shown to reduce the risk of recurrence by approximately 50% at 10 
years and risk of breast cancer death by approximately 20% at 15 years.28  
 
Chemotherapy is typically administered as a combination of drugs and these regimes are usually 
given for 3 to 6 months after surgery.3 It is estimated that approximately 19% of women with 
stage I/II breast cancer and 82% of women with stage III breast cancer receive any 
chemotherapy.7 Adjuvant chemotherapy significantly reduces the risk of recurrence and has been 
shown to reduce annual breast cancer death rates by approximately 38% among women aged ≤50 
years at diagnosis and 20% among women aged 50-69 years at diagnosis.29  
 
Hormone therapy is generally started after the completion of radiation and chemotherapy, if 
needed, for women with HR-positive tumors. The standard hormone therapy for premenopausal 
women is tamoxifen, a selective estrogen receptor modulator that interferes with estrogen binding 
to estrogen receptors, which is typically administered for at least 5-years. Adjuvant tamoxifen 
significantly reduces the risk of recurrence by approximately 40-50% in the first 10 years and 
reduces the risk of breast cancer death by approximately one-third in the first 15 years.30 
Postmenopausal women receive either aromatase inhibitors, which block the production of 
estrogen by preventing the conversion of androgens to estrogen, and/or tamoxifen for 5 to 10 
years.31 Overall, hormone therapy has also been shown to significantly reduce the risk of 
recurrence and breast cancer death in HR-positive tumors.31 However, clinical trials are ongoing 
to determine the optimal timing and duration of hormone therapy.3 
 
Tumors with HER-2 expression benefit from targeted therapies, which inhibit the growth of 
HER-2 proteins. Trastuzumab, a monoclonal antibody that targets the HER-2 protein, has become 
a standard part of treatment for HER-2 positive breast tumors.3 When combined with 
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chemotherapy, trastuzumab has been shown to reduce recurrence risk by 52% and risk of breast 
cancer death by 33% for early-stage HER-2 positive breast tumors.32  
 
1-5d. Age at diagnosis 
 
Overall, the median age of breast cancer diagnosis is 62 years and the median age of breast cancer 
death is 68 years in the United States.14 It is estimated that <2% of invasive breast cancer cases 
are diagnosed among women aged ≤35 years and most breast cancers occur among women aged 
≥65 at diagnosis.14,33 Previous studies have found that women diagnosed at a younger age tend to 
be diagnosed at a later stage34,35 and with ER-negative tumors,36,37 and subsequently have poorer 
overall survival compared to older women.35,37-39 Menopausal status is also intrinsically tied to 
age and breast tumors that develop in premenopausal women tend to be associated with more 
aggressive tumor biology and more likely to be associated with BRCA1 mutations than 
postmenopausal breast cancer. 40,41 It is estimated that women aged <40 years at breast cancer 
diagnosis have a 5-year relative survival rate between 78-84% and women aged >60 years at 
diagnosis have a 5-year relative survival rate exceeding 90%.36,41 The prognosis of older women 
also depends on the prevalence of comorbidities and reduced life expectancy, which can lead to 




Although breast cancer incidence is higher among white women, survival rates are lower among 
African-American women. In the United States, 5-year survival rates are approximately 91% 
among white women and 81% among African-American women.14 Disparities in breast cancer 
survival are complex and may be due to several factors. Specifically, African-American women 
are more likely to be diagnosed at a younger age, and with poor prognostic factors (e.g., late 
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stage, hormone-receptor negative tumors).45 In addition, differences in mammographic screening, 
access to treatment, comorbidities, and socioeconomic factors may play a role.45 Although this 
dissertation does not explore factors by race, future studies are needed in more diverse 
populations. 
 
1-6. Long-term mortality in breast cancer survivors 
 
Epidemiologic studies have primarily examined long-term mortality in cohorts of breast cancer 
survivors only46-54 with comparisons to the general population in a few studies.55-59 Several 
studies have found that breast cancer survivors continue to have a higher risk of death from any 
cause even 10-20 years after diagnosis relative to the general population.55-57 In addition, one 
prior study found that breast cancer survivors had an almost 4-fold higher risk of all-cause 
mortality, primarily due to breast cancer death, compared with the general population and 
survivors still had a 6-fold increased risk of breast cancer mortality even 25 years after 
diagnosis.55  However, survivors diagnosed at older ages or with early stage disease may be more 
likely to die of conditions unrelated to their malignancy.47,48,51 Only two prior studies have 
examined all-cause mortality in women with breast cancer relative to a cancer-free comparison 
from the same cohort60,61 and none have examined this association by tumor characteristics, age at 
diagnosis, and temporal patterns. Therefore, it is difficult to determine if higher long-term 
mortality is driven by breast cancer and its related treatment or may also be in part due to 
increasing age, as well as menopausal status, lifestyle and other health factors. 
 
1-7. Cardiovascular disease (CVD) 
 
CVD is the leading cause of morbidity and mortality among women in the United States.62 In the 
United States, it is estimated that approximately 1 in 3 women have CVD (~47.8 million women) 
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and 1 in 4 female deaths are due to CVD.63,64 Risk factors for CVD can be broadly categorized as 
non-modifiable and modifiable. Non-modifiable risk factors include advancing age, African-
American race, low socioeconomic status, and family history of CVD.62 Modifiable risk factors 
include physical inactivity, smoking, poor diet (e.g., high in saturated fats), obesity, high 
cholesterol and other lipids, hypertension, and diabetes.62  
 
1-7a. CVD in breast cancer survivors 
 
For breast cancer survivors, CVD represents the leading cause of noncancer death.51 Among 
breast cancer survivors aged ≥50 years, approximately 35% of non-breast cancer deaths are due 
to CVD.51 Furthermore, women diagnosed at an early stage or at an older age, may be more likely 
to die from CVD than breast cancer.52,53 Although several studies have reported an increased risk 
of CVD mortality in breast cancer survivors compared to the general population,55,58,65 
comparisons to cancer-free women within the same cohort are limited to two prior studies60,61 and 
none have specifically evaluated whether CVD-mortality varies by tumor characteristics, age at 
diagnosis, and by long-term temporal patterns. 
 
1-7b. Etiology of cardiovascular disease in breast cancer survivors 
 
The etiology of CVD in breast cancer survivors is not well understood. It is hypothesized that an 
increased CVD risk may result from cardiotoxic effects of breast cancer treatment, which may 
begin to manifest at the time of treatment or as a late effect of treatment (Table 1-2).63,66-69   






There is a considerable amount of evidence supporting the role of radiation therapy on 
cardiovascular toxicity.70 It is hypothesized that radiation, specifically to the left side of the chest 
wall, may increase CVD mortality by causing injury to the cardiac muscle. Yet some studies have 
shown no association between radiation and CVD mortality among women with left sided tumors 
compared to women with women with right-sided tumors.71-73 It is also possible that current 
radiation therapy regimes, which are more targeted, are associated with a lower risk of 
cardiotoxic effects than older regimes.72,74 Importantly, the effects of radiation therapy on CVD 
could occur as early as 5 years after therapy with some studies suggesting that risk may persist up 
to 30 years after treatment.54,74,75 This underlies the importance of examining long-term mortality 




Cardiovascular toxicity induced by chemotherapy has been well established.70,76 Anthracyclines, 
which have been used to treat breast cancer since the 1970s, have been associated with adverse 
cardiovascular effects including left ventricular dysfunction and heart failure.63,68  Older women 
and patients exposed to concomitant chemotherapy and radiation therapy are at the highest risk 
for cardiotoxic effects of anthracyclines.63 Importantly, cardiotoxicity from anthracyclines can 
manifest either early or late after treatment. Alkylating agents (e.g., cisplatin and 
cyclophosphamides), taxanes, and antimetabolites have also been associated with adverse 
cardiovascular effects.63 Chemotherapy may also indirectly impact CVD by inducing treatment-
related menopause in premenopausal women.77 Early menopause is associated with an increased 
risk of CVD due to lower levels of endogenous estrogen and subsequent unfavorable changes in 





Aromatase inhibitors, which deplete estrogen production, have been associated with a possible 
increased risk of CVD due to an increase in lipid and apolipoprotein concentrations.76,81 
Conversely, tamoxifen has been shown to exert beneficial effects on the cardiovascular system, 
which may be driven by lowering levels of total cholesterol, LDL cholesterol, apoprotein A1, and 
lipoprotein.76 Despite these favorable effects on lipid profiles, large clinical trials have failed to 
show a protective effect of tamoxifen on cardiovascular endpoints.63 Furthermore, some small 
studies have reported an increase in triglycerides among women treated with tamoxifen.82,83 
 
HER-2 targeted therapies 
 
Trastuzumab, a monoclonal antibody, has been associated with heart failure and left ventricular 
dysfunction, particularly when administered concomitantly or after anthracylcines.69 Other 
targeted therapies, such as lapatinib, a small-molecule tyrosine kinase inhibitor approved for 
treatment of HER-2 metastatic cancer, may also be associated with a higher incidence of adverse 
cardiac events.63 
 
Shared factors associated with breast cancer and CVD 
 
There are several common factors between breast cancer and CVD incidence (Table 1-3).63 These 
include increasing age, early menopause, hormone replacement therapy, smoking, obesity, and 
physical inactivity.63,84-86 These shared factors underlie the importance for a cancer-free 
comparison within the same cohort to determine if breast cancer and its treatment have an 
independent effect on CVD burden in breast cancer survivors after accounting for these factors.  
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1-7c. CVD risk factors in breast cancer survivors 
 
Breast cancer survivors have a higher prevalence of CVD risk factors, including 
hypercholesterolemia, hypertension, and diabetes, compared to cancer-free women.87,88 However, 
whether CVD risk factors develop prior or after a breast cancer diagnosis remains unclear. A 
recent study found that adolescent and young adult breast cancer survivors had a higher incidence 
of diabetes and dyslipidemia, but not hypertension, compared to age-matched cancer-free women 
after adjusting for other risk factors including smoking, and overweight/obesity status.88 CVD 
risk factors may develop in breast cancer survivors due to treatment related effects. However, 
CVD risk factors are also common among cancer-free women due to factors such as increasing 
BMI, physical inactivity, and an unhealthy diet.64 No prior study has examined incident CVD risk 
factors in adult breast cancer survivors compared to cancer-free women within the same cohort. 
 
1-8. Bone loss  
 
Among women aged ≥50 years in the United States, it is estimated that approximately 15.4% 
have osteoporosis and 51.4% have low bone density.89 Osteopenia and osteoporosis, both 
common conditions associated with varying degrees of bone loss, are initially diagnosed with 
measurements of bone mineral density (BMD) obtained from dual x-ray absorptiometry (DXA) 
scans. Although there are several methods to measure BMD, DXA scans are considered the gold 
standard. BMD is usually expressed in relative terms with a T-score calculated as a [(patient’s 
BMD-young normal mean BMD)/ standard deviation of young normal mean BMD].90 Based on 
WHO diagnostic criteria, osteopenia is defined as lower than average bone density with a T-score 
ranging from -1 to -2.5 (e.g., BMD levels are 1 to 2.5 standard deviations below the average level 
for young adults at peak bone mass).90-92 Osteoporosis, characterized by even lower bone density, 
is defined as a T-score less than -2.5.90-92 Among cancer-free women, loss in bone density is 
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primarily due to advancing age and menopause induced estrogen deficiency.93,94 Modifiable 
factors also contribute to bone loss including low body weight, lack of physical activity, excess 
alcohol consumption, family history of bone fracture, cigarette smoking, low calcium intake, and 
vitamin D deficiency.93,94 Untreated bone loss can lead to subsequent fractures, decreased quality 
of life, and death.93 However, bone loss can be prevented with screening, lifestyle interventions 
(e.g., physical activity, smoking cessation, limiting alcohol intake, and adequate calcium and 
vitamin D intake), and therapy (e.g., bisphosphonates).93 
 
1-8a. Bone loss in breast cancer survivors 
 
Bone loss is highly prevalent among postmenopausal breast cancer survivors with up to 80% 
experiencing bone loss.77 In addition, previous studies have shown that breast cancer survivors 
have a higher rate of fractures compared to cancer-free women.95,96 For example, one study found 
that breast cancer survivors were almost 5-fold more likely to experience a vertebral fracture 
compared to the general population.95 Few epidemiological studies have examined bone loss in 
breast cancer survivors compared to cancer-free women within the same cohort. Furthermore, 
these studies have been primarily conducted among older and long-term survivors and have not 
examined risk of bone loss by tumor subtypes and detailed treatment regimes.  
 
1-8b. Etiology of bone loss in breast cancer survivors 
 
The etiology of bone loss in cancer survivors may be due to both advancing age and menopause 
in addition to the effects of breast cancer treatment. Advancing age is associated with greater 
bone resorption and less bone formation, while menopause accelerates bone loss due to lower 
levels of endogenous estrogen.97,98 Although the mechanisms underlying bone loss after 
menopause are not fully understood, it is well-established that estrogen plays a fundamental role 
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in maintaining bone density and estrogen deficiency is associated with a large increase in bone 
resorption.99 Treatment related effects on bone loss have been commonly reported in survivors 
and breast cancer treatment can cause direct as well as indirect effects on bone health. Hormone 
therapies, such as tamoxifen and aromatase inhibitors, have been shown to increase the risk of 
bone loss in breast cancer survivors by subsquently reducing estrogen levels. Although tamoxifen 
may be protective against bone loss in postmenopausal women, it has been reported to increase 
bone loss in premenopausal women.100,101 The underlying mechanisms of bone loss in breast 
cancer survivors may also be due to the direct toxic efects of chemotherapy on bone formation 
cells as well as treatment induced premature menopause.102  
Outline of the dissertation 
 
The chapters that follow will examine mortality, CVD risk factors, and bone loss in breast cancer 
survivors relative to cancer-free women. Chapter 2 examines the risk of long-term all-cause and 
CVD-related mortality among breast cancer survivors relative to cancer-free women in a 
population-based cohort study with over 20 years of follow-up. Chapter 3 evaluates the risk of 
developing CVD risk factors shortly after diagnosis in breast cancer survivors compared to 
cancer-free women in a cohort of women with familial risk for breast cancer. Chapter 4 examines 
the risk of bone loss in breast cancer survivors compared to cancer free women in a cohort of 
women with a family history of breast cancer. Chapter 5 concludes with a summary of our results, 
implications for breast cancer survivors, and future research directions.
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Cancer site N (%) 
Breast 3,560,570 (44%) 
Uterine 757,190 (9%) 
Colon and rectum 727,350 (9%) 
Thyroid 630,660 (8%) 
Melanoma 612,790 (8%) 
Non-Hodgkin lymphoma 324,890 (4%) 
Lung and bronchus 288,210 (4%) 
Uterine cervix 282,780 (3%) 
Ovary 235,200 (3%) 
Kidney 204,040 (3%) 
All sites 8,156,120  
Adapted from Miller et al. (2016)10 
Source: Surveillance Research Program, Division of Cancer Control and Population Sciences, National Cancer 
Institute, Bethesda, MD 
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Table 1-2. Common breast cancer treatment and cardiovascular adverse effects 




Coronary artery disease, cardiomyopathy, valvular disease, 




Left ventricular dysfunction, heart failure, myocarditis, 
pericarditis, atrial fibrillation, ventricular tachycardia, 
ventricular fibrillation 
 
Alkylating agents  
 
Left ventricular dysfunction, heart failure, myocarditis, 
pericarditis, arterial thrombosis, bradycardia, atrial 




Bradycardia, heart block, ventricular ectopy 
Antimetabolites  
 
Coronary thrombosis, coronary artery spasm, atrial 
fibrillation, ventricular tachycardia, ventricular fibrillation 
 
Hormonal therapy  
 
Venous thrombosis, thromboembolism, peripheral 
atherosclerosis, dysrhythmia, valvular dysfunction, 
pericarditis, heart failure 
 
HER-2 directed therapies  
 
Left ventricular dysfunction, heart failure 













Table 1-3. Factors associated with developing breast cancer and cardiovascular disease 
 Risk of breast cancer Risk of cardiovascular disease 
Increasing age ↑ ↑ 
Healthy Dieta ↓ ↓ 
Western Dietb ↑ ↑ 
Light-moderate alcohol intake ↑ ↓ 
Red/processed meat ↑ ↑ 
Physical activity ↓ ↓ 
Sedentary lifestyle ↑ ↑ 
Premenopausal obesity ↓ ↑ 
Postmenopausal obesity ↑ ↑ 
Smoking ↑ ↑ 
Early menarche ↑ ↑ 
Early menopause ↓ ↑ 
Hormone replacement therapy ↑ ↑ 
Adapted from Mehta et al. (2018)63 
↑ indicates an increased risk; ↓ indicates a decreased risk 
a High in vegetables and fruits, poultry, fish, low-fat dairy products and whole grains 
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Chapter 2.  
 









Background: Long-term survival is common after breast cancer with overall 5-year survival 
rates now exceeding 90%. Understanding the risk of mortality in breast cancer survivors by tumor 
characteristics, age at diagnosis, and temporal patterns relative to cancer-free women will inform 
the effect of breast cancer and its related treatment on long-term survival and the need for 
increased medical surveillance and targeted interventions to reduce mortality.  
 
Methods: We compared all-cause and cardiovascular disease (CVD)-related mortality in 628 
women with early stage breast cancer and 3,140 age-matched cancer-free women in the CLUE II 
(“Give Us a Clue to Cancer and Heart Disease”) cohort with over 20 years of follow-up. We 
calculated multivariable adjusted hazard ratios (HRs) and 95% confidence intervals (CIs) for all-
cause and CVD-related mortality using Cox proportional hazards regression. For CVD-related 
mortality, we also calculated sub-distribution HRs (sdHRs) using the Fine and Gray model to 
account for non-CVD death as a competing event. Models were stratified by tumor 
characteristics, age at diagnosis, and time since diagnosis. 
 
Results: Over a median of 10.4 years of follow-up, 916 deaths were identified including 249 
CVD-related deaths. The leading causes of death among breast cancer survivors were cancer 
(41%) followed by CVD (20%). Overall, in multivariable adjusted models, breast cancer 
survivors had a higher risk of dying compared to their cancer-free peers (HR=1.79, 95% CI=1.53-
2.09) and this increased risk remained irrespective of stage and estrogen-receptor (ER)-status. 
Relative to cancer-free women, higher all-cause mortality persisted even 15 years after diagnosis 
among breast cancer survivors overall; however, breast cancer survivors diagnosed at age ≥70 
years had a steady increase in all-cause mortality over time. An increased risk of CVD-related 
death was evident only after 8 years in breast cancer survivors compared to cancer-free women 
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(HR=1.71, 95% CI=1.03-2.83; sdHR=1.65, 95% CI=1.00-2.73), particularly among survivors 
with ER-positive tumors (HR=1.92, 95% CI=1.11-3.33; sdHR=1.85, 95% CI=1.06-3.20) and 
survivors aged ≥70 years at diagnosis (HR=2.43, 95% CI=1.40-4.21; sdHR=2.24, 95% CI=1.29-
3.88). 
 
Conclusion: Breast cancer survivors continue to have higher all-cause mortality due to their 
disease even 15 years after diagnosis; further research is needed to understand the persistent 
higher risk of all-cause mortality among all breast cancer survivors and the increasing risk over 
time among elderly breast cancer survivors. Early identification of CVD risk factors and 
interventions shortly after diagnosis may be warranted, particularly among elderly and ER-




In recent decades, advances in effective screening and treatment strategies have led to an 
increasing population of over 3.5 million breast cancer survivors in the United States.1 With 5-
year survival rates for breast cancer now exceeding 90%,2  many women diagnosed with breast 
cancer will become long-term survivors at risk for disease progression, short- and long-term 
effects of treatment, and developing other co-morbidities. Therefore, it is of increasing 
importance to understand whether these women need increased medical surveillance and targeted 
interventions to reduce the risk of long-term mortality.  
 
Previous studies on long-term mortality in breast cancer survivors have been primarily conducted 
among survivors only3-12 with comparisons to the general population in a few studies.13-17 Results 
from these studies suggest that excess all-cause mortality persists even 10-20 years after a breast 
cancer diagnosis, and is even higher among older survivors, relative to the general population.13-17 
Furthermore, many survivors are likely to die of conditions unrelated to their primary 
malignancies.6,7 Notably, cardiovascular disease (CVD) is an issue of growing concern, 
particularly among women with favorable breast cancer phenotypes and among women 
diagnosed at an older age.5-12 However, prior studies have been limited by either lacking 
individual level data on potential confounders or a cancer-free comparison; therefore it remains 
unclear whether all-cause and CVD-mortality may be due to breast cancer and its related 
treatment or whether the effects of aging, undergoing menopause, or lifestyle factors may also 
play a role. 
 
Two recent studies have examined all-cause and CVD mortality in breast cancer survivors 
relative to cancer-free women within the same cohort.18,19 Results from these studies suggest that 
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breast cancer survivors have a higher risk of dying from any cause even after accounting for age, 
menopause, and lifestyle factors.18,19 In addition, one of these studies observed that risk of CVD 
may manifest only 7 years after diagnosis.18 However, only one study examined the association 
by age at diagnosis and was restricted to post-menopausal survivors.19 Furthermore, only one 
prior study had information on pre-diagnostic exposures19 and only one examined temporal 
trends.18 Both studies were limited by duration of follow-up and lacked detailed information on 
stage and breast cancer subtype.  
 
To further understand long-term mortality in breast cancer survivors, we examined all-cause and 
CVD-related mortality in women diagnosed with breast cancer relative to age-matched cancer-
free women in the community-based CLUE II  (“Give use a Clue to Cancer and Heart Disease”) 
cohort with over 20 years of follow-up. We also explored whether these associations differed by 





Study participants and design  
 
The CLUE II (“Give use a Clue to Cancer and Heart Disease”) cohort was formed in 1989 when 
32,894 residents of Washington County, Maryland and the surrounding area completed an 
enrollment questionnaire and provided blood samples. Participants were subsequently followed 
with mailed questionnaires in 1996, 1998, 2000, 2003, and 2007. Updates on cancer incidence 
and mortality are conducted annually. The CLUE II study is approved by The Institutional 
Review Board of Johns Hopkins University. 
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For the present analysis, women aged 18 to ≤80 years with no history of cancer (except for non-
melanoma skin cancer or cervical carcinoma in situ) at study enrollment were prospectively 
followed for breast cancer occurrence (N=14,420). All women diagnosed with a first primary 
breast cancer (stage I-III) through December 31st, 2015 were identified (n=628). Women 
diagnosed with stage 0, stage IV, or unknown breast cancer stage were excluded (n=161). A 
comparison group was then sampled from the same cohort. To ensure a similar distribution in age 
and follow-up time, five cancer-free women were randomly sampled without replacement and 
matched on age at diagnosis and time since enrollment to each woman diagnosed with breast 
cancer. The index date was the date of breast cancer diagnosis for women diagnosed with breast 
cancer. For comparison women (i.e., cancer-free women), the index date was the date of breast 
cancer diagnosis for their matched breast cancer survivor. Cancer-free women had to be alive and 
free of cancer at their index date. 
 
Ascertainment of breast cancer  
 
Our exposure of interest was a first primary stage I-III breast cancer diagnosis. In CLUE II, breast 
cancer diagnoses have been ascertained via linkage to the Washington County Cancer Registry 
and the Maryland Cancer Registry, as well as through medical record review and death 
certificates.20 Information on tumor characteristics including date of diagnosis, age at diagnosis, 
stage, tumor size, and joint estrogen receptor (ER)/progesterone receptor (PR) status have been 
ascertained from cancer registries, medical record review, and pathology records. Initial treatment 
(none, surgery, chemotherapy, radiation and/or hormone therapy) was abstracted from medical 
records.   
 
Ascertainment of death 
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Deaths were identified via death certificates, next of kin, obituaries, and the National Death Index 
through December 31, 2015. Death certificates were reviewed to identify the primary cause of 
death. We did not incorporate information on the contributing cause of death. Cause of death was 
coded using ICD-9 codes through 1998 and ICD-10 codes for all deaths after 1998. We 
considered deaths from any cause and deaths due to CVD. Deaths from CVD were identified if 
the following ICD codes were listed as the primary cause of death: 390-398, 402, 404, 410-429, 
I00-I09, I11, I13, and I20-I51. These codes were selected a priori to primarily represent deaths 
due to heart disease including ischemic heart disease, hypertensive heart disease, pulmonary heart 
disease, and other heart diseases (e.g., cardiomyopathy and heart failure). We did not include 
other CVD deaths due to essential hypertension, secondary hypertension, or cerebrovascular 
disease.  
 
Ascertainment of covariates 
 
Covariate information used in this analysis was from the interviewer-administered enrollment 
questionnaire in 1989. The questionnaire included information on date of birth, anthropometric 
factors (weight, height), lifestyle behaviors (smoking, alcohol use), reproductive/hormonal factors 
(oral contraceptive use, hormone use, and menopause status), medication use within the past 48 
hours (e.g., medication for blood pressure, cholesterol, cardiovascular disease, and diabetes), and 
socio-demographic indicators (race/ethnicity, education). In addition, resting blood pressure and 





Characteristics of breast cancer survivors and cancer-free women were compared with frequency 
distributions for categorical variables and means (SDs) for continuous variables. Breast cancer 
clinical and treatment characteristics were also summarized for breast cancer survivors.  
 
Proportional mortality ratios 
 
We calculated proportional mortality ratios (PMRs) among women with and without breast 
cancer to describe the contributions of specific causes of death (cancer, cardiovascular disease, 
other vascular disease including cerebrovascular and hypertensive disease, pulmonary disease, 
dementia, diabetes, infection, and other).  PMRs were defined as the number of deaths due to a 
specific cause over the total number of deaths. PMRs were calculated overall and by tumor 




We calculated Kaplan-Meier failure curves and used Cox proportional hazards regression to 
calculate hazard ratios (HRs) and 95% confidence intervals (CIs) for all-cause mortality in breast 
cancer survivors relative to cancer-free women. Time since index date was used as the underlying 
time metric. Women contributed person-time from the index date to the date of death or 
December 31st, 2015, whichever occurred first.  
 
To account for multiple potential confounders, we used inverse probability weighting (IPW) to 
adjust for potential confounding in Kaplan Meier failure curves and regression models.21-23 We 
used logistic regression models to construct the weights. Specifically, we fit a null model to 
calculate the marginal probability of being diagnosed with breast cancer (i.e., numerator of the 
weights) and then regressed breast cancer status on the potential confounders to obtain predicted 
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probabilities of breast cancer conditional on the potential confounders (i.e., denominator of the 
weight).24 Robust standard errors were used to account for weights in the models. Potential 
confounders were identified a priori as variables that may be associated with both breast cancer 
incidence and mortality. These included menopausal status (premenopausal, postmenopausal), 
education (<12, 12, >12 years), smoking status (never, former, current), alcohol intake (0-3 drinks 
per month, ≥1 drinks per week), body mass index (BMI) (<25, 25-<30, ≥30kg/m2) and oral 
hormone use (ever, never). Age was also included to account for any potential residual 
confounding. We assessed the proportional hazards assumption graphically with log-log survival 
plots and Schoenfeld residuals; there was no indication that the assumption of proportional 
hazards was violated.  
 
We conducted several stratified analyses. First, we explored whether all-cause mortality varied 
among breast cancer survivors by tumor characteristics relative to cancer-free women. 
Specifically, we classified breast cancer survivors by stage (I, II, III) and ER-status (ER-positive, 
ER-negative). Second, to examine whether the association varied by time since index date, we 
stratified regression models by 0-5, >5-15 years, and >15 years since index date. These cut points 
were determined a priori and chosen based on clinically meaningful thresholds for risk of 
recurrence.25 We then also restricted breast cancer survivors to those with the most favorable 
phenotypes (i.e., stage I or ER-positive tumors) and stratified the association by time. Finally, we 
stratified our models by age at index date (<70, ≥70 years) to determine whether the association 
varied by age. We chose the cut point of 70 years to be consistent with previous literature.19 To 
test for significant differences across strata of time and age, we used multiplicative interaction 






To calculate risk of CVD-related mortality, we used a competing risk approach to account for 
non-CVD mortality as a competing event. Here, other causes of death (e.g., breast cancer) may 
preclude the event of interest (e.g., CVD-related mortality) and therefore remove women from the 
risk set before the event of interest is observed.26 First, we used a non-parametric estimator of the 
cumulative incidence function to account for competing events.27 Second, we estimated both the 
cause-specific hazard ratios (csHRs) and subdistribution hazard ratios (sdHRs).26,28,29 csHRs for 
CVD-related mortality were estimated using Cox proportional hazards regression and non-CVD 
mortality was censored at the time of death. csHRs provided insight into whether breast cancer 
survivors had a higher instantaneous rate of CVD-related mortality but may not be interpreted as 
having a direct relationship to the probability of CVD-related mortality.26 In this analysis, we 
interpret csHRs as the rate of CVD-related mortality in breast cancer survivors relative to cancer-
free women among women who are still alive.26,28 sdHRs for CVD-related mortality were 
estimated using Fine and Gray regression models, which account for the influence of non-CVD 
mortality as a competing event, and can be interpreted as having a direct relationship to the 
probability of CVD-related mortality.26,28 Here we interpret sdHRs as the risk of CVD-related 
mortality in breast cancer survivors compared to cancer-free women.28   
 
We accounted for multiple potential confounders and assessed the proportional hazards 
assumption with the same methods used for analyses examining all-cause mortality. Since the 
assumption of proportional hazards by breast cancer status was violated for CVD-related 
mortality, these models should be interpreted as the weighted average effect over the follow-up 
period.26,30 In addition, we also report this association stratified by follow-up time. 
 
We conducted the same series of stratified analyses as all-cause mortality. However, we stratified 
regression models by 0-8 vs. >8 years for CVD-related mortality to examine whether the 
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association varied by time. These cut points for CVD-related mortality were determined 
empirically based on the cumulative incidence curves. We did not include results for CVD-related 




We conducted a number of sensitivity analyses. First, we additionally adjusted for hypertension 
(yes, no), dyslipidemia (yes, no), diabetes medication (yes, no) and CVD medication (yes, no) in 
multivariable models. Second, we additionally adjusted multivariable models for race (white, 
black, other). Third, we adjusted for elapsed time from completion of the 1989 questionnaire to 
the index date to account for possible misclassification of covariates measured more distal to the 
index date. Fourth, we stratified our models by year of index date (<2000, ≥2000) to examine 
whether mortality trends may differ due to advances in breast cancer treatment over time. Fifth, 
we stratified regression models by an indicator for matched set to preserve the matching during 
follow-up. We did not use this as our primary approach since our analyses would have been 
limited by highly stratified data, particularly among subgroup analyses. Finally, since our 
comparison group could not develop an incident breast cancer during follow-up, we conducted a 
sensitivity analysis that treated breast cancer as a time-varying exposure to determine whether 
this may have biased our results. Specifically, in these analyses, women in the comparison group 
(i.e., unexposed) who were diagnosed with breast cancer after their index date were censored on 
their diagnosis date and at this time became members of the breast cancer group (i.e., exposed). 
We did not use this as our primary approach because the time of entry for women who were 
diagnosed with breast cancer after their index date (~3% of women in the comparison group) is 
not the date of diagnosis. This approach limits the ease of interpretability for our research 
question, which was focused on mortality after a breast cancer diagnosis and looking at trends 
over time since diagnosis. Furthermore, given that breast cancer is a rare occurrence and, in this 
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data, only 3% of the comparison group developed breast cancer, additional analytic approaches 
will likely be similar to our primary approach. 
 
Analyses were conducted using SAS version 9.4 (SAS Institute Inc., Cary, NC, USA) and Stata 
version 14.0 (StataCorp LP, College Station, TX, USA). All statistical tests were two-side and P 






Table 2-1 describes characteristics of 3,768 women by breast cancer status (628 breast cancer 
survivors and 3,140 cancer-free women). As expected, the overall distributions of covariates were 
similar in breast cancer survivors compared to cancer-free women (mean age: 64.5 vs. 64.4 years; 
post-menopausal: 58.8 vs. 56.6%; mean BMI: 26.5 vs. 26.1 kg/m2; never smokers: 61.8 vs. 
61.1%). In addition, mean total cholesterol and blood pressure measurements and the proportion 
of heart disease and diabetes medications were similar among breast cancer survivors and cancer-
free women at study enrollment. Among survivors, the median year of breast cancer diagnosis 
was 2002 (25th-75th percentile: 1996-2009) and women were more likely to be diagnosed at an 
early stage and with ER-positive tumors.  
 
Leading causes of death  
 
During 10.4 median years of follow-up, 34.6% of breast cancer survivors and 22.3% of cancer-
free women died from any cause (Appendix 2-1; Appendix 2-2). Overall, cancer (41%) and CVD 
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(20%) were the leading causes of death in breast cancer survivors and CVD (29%) and cancer 
(17%) were the leading causes of death in women without breast cancer (Figure 2-1 A). Among 
women with stage I breast cancer, both cancer and CVD were the leading causes of death, and 
cancer was the leading cause of death among women with ER-positive tumors (Figure 2-1 B-C).  
 
When we stratified PMRs by follow-up time, cancer remained the leading cause of death among 
breast cancer survivors and CVD remained the leading cause of death among cancer-free women 
throughout follow-up (Figure 2-2 A-C). The leading cause of death varied by time among women 
with stage I breast cancer (Figure 2-2 D-F) and cancer remained the leading cause of death over 
time in women with ER-positive tumors (Figure 2-2 G-I). 
 
Among women aged <70 at index date, cancer was the leading cause of death for both women 
with and without cancer (Figure 2-3 A). However, among women aged ≥70 years at index date, 
CVD was the leading cause of death for both women with and without breast cancer (30% and 
33%, respectively) (Figure 2-3 B). Cancer remained the leading cause of death throughout 
follow-up among women diagnosed at <70 years (Figure 2-3 C-E) and the leading cause of death 
varied by time among women diagnosed at ≥70 years (Figure 2-3 F-H).  
 
All-cause mortality  
 
Overall, death from any-cause was higher among breast cancer survivors relative to cancer-free 
women (HR=1.79, 95% CI=1.53-2.09) (Figure 2-4; additional numerical results are in Appendix 
2-3). Stratification by cancer stage indicated that risk of all-cause mortality was greater with 
increasing stage when compared to cancer-free women (stage I: HR=1.53, 95% CI=1.25-1.86; 
stage II: HR=1.94; 95% CI=1.53-2.47; stage III: HR=4.86, 95% CI=3.12-7.56) (Figure 2-5 A). 
ER-positive and ER-negative survivors also had higher all-cause mortality compared to cancer-
 38 
free women (HR=1.81, 95% CI=1.52-2.14; HR=1.98, 95% CI=1.41-2.76, respectively) (Figure 
2-5 B). 
 
We then evaluated risk of all-cause mortality by time since diagnosis (Figure 2-4). Overall, death 
from any cause remained higher, even 15 years after diagnosis, in breast cancer survivors 
compared to cancer-free women (0-5 years: HR=1.91, 95% CI=1.45-2.52; >5-15 years, HR=1.70, 
95% CI=1.37-2.11; >15 years, HR=1.84, 95% CI=1.28-2.66; p-interaction=0.91) (Figure 2-4). 
Survivors with stage I and ER-positive breast cancer also had an increased risk of all-cause 
mortality compared to cancer-free women even 15 years after diagnosis (Figure 2-5 A-B). 
 
Next we examined all-cause mortality in breast cancer survivors compared to cancer-free women 
stratified by age at index date and then jointly stratified by age and time since index date (Table 
2-2). Among women aged <70 years, risk of all-cause mortality was over two-fold higher among 
breast cancer survivors relative to cancer-free women (HR=2.20, 95% CI=1.72-2.80). Results 
were slightly attenuated among women aged ≥70 years (HR=1.71, 95% CI=1.42-2.06). Among 
women aged <70 years, risk of all-cause mortality was highest within the first 5 years after 
diagnosis in breast cancer survivors relative to cancer-free women (HR=3.52, 95% CI=2.19-
5.63), however higher mortality persisted over time (>5-15 years, HR=1.78, 95% CI=1.24-2.56; 
>15 years, HR=2.05, 95% CI=1.28-3.29; p-interaction=0.28). Among women aged ≥70 years, 
risk of all-cause mortality significantly differed by time in breast cancer survivors compared to 
cancer-free women (p-interaction=0.05). Specifically, survivors had a 44% increased risk of all-
cause mortality compared to cancer-free women within the first 5 years after diagnosis (HR=1.44, 
95% CI=1.01-2.04) and an almost 3-fold higher risk of all-cause mortality after 15 years 





Overall, CVD-related mortality was higher among breast cancer survivors compared to cancer-
free women; however, results were not statistically significant and further attenuated with 
competing risk regression (csHR=1.24, 95% CI=0.89-1.72; sdHR=1.09; 95% CI=0.78-1.51) 
(Figure 2-6; additional numerical results are in Appendix 2-3). The attenuation of the sdHR 
suggests that more breast cancer survivors had a competing event (i.e., non-CVD mortality such 
as breast cancer mortality) and therefore, breast cancer survivors are kept in the risk set in a 
greater proportion than those without breast cancer in competing risk regression.26  
 
We observed no significant associations for CVD-related mortality among breast cancer survivors 
by stage relative to cancer-free women (Figure 2-7 A). However, women with ER-positive breast 
cancer had significantly higher CVD-related mortality compared to cancer-free women, yet 
results were slightly attenuated in competing risk regression (csHR=1.45, 95% CI=1.02-2.06; 
sdHR=1.28, 95% CI=0.90-1.82) (Figure 2-7 B). We observed no significant association with 
CVD-related mortality in ER-negative breast cancer survivors relative to cancer-free women 
(Figure 2-7 B). Results for the competing event, non-CVD mortality, stratified by tumor 
characteristics are shown in Appendix 2-4.  
 
We then examined the risk of CVD-related mortality by time since diagnosis (Figure 2-6). 
Overall, risk of CVD-related death appeared to differ by time, although the difference was not 
statistically significant (p-interaction=0.14 and 0.13 for csHRs and sdHRs, respectively). Within 
the first 8 years after diagnosis, there was no difference in CVD-related mortality among breast 
cancer survivors compared to cancer-free women (csHR=0.99, 95% CI=0.59-1.66; sdHR=0.94, 
95% CI=0.56-1.58). After 8 years, risk of CVD-related mortality was significantly higher among 
breast cancer survivors relative to cancer-free women (csHR=1.71, 95% CI=1.03-2.83; 
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sdHR=1.65, 95% CI=1.00-2.73). Results for non-CVD mortality stratified by time are shown in 
Appendix 2-5.  
 
CVD-related mortality did not appear to differ by time in stage I breast cancer survivors relative 
to cancer-free women (p-interaction=0.42 for csHRs; p-interaction=0.45 for sdHRs) (Figure 2-7 
A). However, an increased risk of CVD-related mortality may begin to manifest 8 years after 
diagnosis in women with ER-positive breast cancer relative to cancer-free women (0-8 years: 
csHR=1.10, 95% CI=0.62-1.93, sdHR=1.06, 95% CI=0.60-1.86; >8 years: csHR=1.92, 95% 
CI=1.11-3.33, sdHR=1.85, 95% CI=1.06-3.20; p-interaction=0.17 for csHRs and sdHRs) (Figure 
2-7 B). Results for non-CVD mortality in stage I and ER-positive survivors stratified by time are 
shown in Appendix 2-5. 
 
Finally, we evaluated CVD-related mortality in breast cancer survivors compared to cancer-free 
women stratified by age at index date (Table 2-3). We observed no significant association 
between breast cancer status and CVD-related mortality among women aged <70 years at index 
date (csHR=0.77, 95% CI=0.35-1.70; sdHR=0.68, 95% CI=0.31-1.49). Among women aged ≥70 
years, breast cancer survivors had significantly higher CVD-related mortality compared to 
cancer-free women, although results were attenuated in competing risk regression (csHR=1.58, 
95% CI=1.10-2.27; sdHR=1.25, 95% CI=0.87-1.80).  
 
In Table 2-3, we further stratified the association jointly by both age and then time, and observed 
no significant temporal trends among women aged <70 years. Among women aged ≥70 years, 
CVD-related mortality appeared to differ by time among breast cancer survivors compared to 
cancer-free women (p-interaction=0.06 for csHRs; p-interaction=0.07 for sdHRs). Specifically, 
we observed no significant association within the first 8-years in breast cancer survivors relative 
to cancer-free women (csHR=1.16, 95% CI=0.67-1.99; sdHR=1.10, 95% CI=0.64-1.88) and an 
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over two-fold higher risk of CVD-related mortality after 8 years (csHR=2.43, 95% CI=1.40-4.21; 
sdHR=2.24, 95% CI=1.29-3.88). Results for non-CVD mortality stratified by age and jointly by 




First, results were similar to our primary analyses when we additionally adjusted for 
hypertension, high cholesterol, diabetes medication and CVD medication in multivariable models 
(Appendix 2-3). Second, results were also similar when we adjusted for race or elapsed time from 
completion of the 1989 questionnaire to the index date (data not shown). Third, analyses that 
stratified by year of index date (<2000, ≥2000) did not significantly differ for all-cause or CVD-
related mortality (data not shown). Fourth, regression models that stratified by an indicator for 
matched set were similar compared to the primary analyses (Appendix 2-7). Finally, in sensitivity 
analyses using a breast cancer diagnosis as a time-varying exposure, 3% of cancer-free women 
developed breast cancer after their index date and thus were censored on their diagnosis date and 
became exposed at that time. Given the small proportion of women who developed breast cancer 
after their index date, overall results in this sensitivity analysis were similar to our primary 




Overall, this study demonstrated that breast cancer survivors had a 79% higher risk of all-cause 
mortality relative to cancer-free women and an increased risk persisted irrespective of stage and 
ER-status for up to 15 years. All-cause mortality was similar by age at diagnosis; however trends 
in all-cause mortality differed by time among younger and older survivors. Women aged <70 
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years at diagnosis had the highest risk of dying within the first 5 years compared to cancer-free 
women of similar age. In contrast, women aged ≥70 years at diagnosis had a steady increase in 
all-cause mortality over time with a 44% increased risk of all-cause mortality within 5 years of 
diagnosis and an almost 3-fold increased risk of all-cause mortality after 15 years. We further 
found that risk of CVD-related mortality may be higher among breast cancer survivors, 
particularly among those diagnosed at an older age or with ER-positive tumors, relative to cancer-
free women. However, a higher risk of CVD-related mortality only begins to manifest after 8 
years post-diagnosis. 
 
To date, only two studies have examined all-cause and CVD-mortality in breast cancer survivors 
relative to cancer-free women within the same cohort.18,19 Our overall finding that risk of all-
cause mortality was higher in breast cancer survivors compared to cancer-free women is 
consistent with these studies.18,19 The first of these studies, conducted by Bradshaw and 
colleagues in the Long Island Breast Cancer Study Project with up to 13.5 years of follow-up, 
found that breast cancer survivors had an 80% increased risk of all-cause mortality compared to 
cancer-free women (HR=1.8, 95% CI=1.5-2.1) even after accounting for age, menopause and 
other potential confounding factors.18 The second study, conducted by Park and colleagues 
among post-menopausal women in the Women’s Health Initiative, reported a higher total 
mortality rate in women with localized breast cancer compared to cancer-free women after 10 
years of follow-up.19 However, these studies did not examine all-cause mortality by breast cancer 
characteristics and were limited by duration of follow-up. Adding to this literature, we also 
observed an increased risk of all-cause mortality irrespective of stage and ER status and even 15 
years after diagnosis among all breast cancer survivors and even among survivors with stage I or 
ER-positive tumors.  
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To our knowledge, this is the first prospective study to examine all-cause mortality stratified 
jointly by age at diagnosis and time since diagnosis in breast cancer survivors compared to cancer 
free women within the same cohort. Although Park and colleagues reported a 20% increased risk 
of all-cause mortality in older breast cancer survivors, aged 70-79 years at diagnosis, compared to 
cancer-free women of similar age (HR=1.20, 95% CI=1.04-1.39), this study did not examine all-
cause mortality among women aged <70 years or by temporal trends. The underlying 
mechanisms of higher all-cause mortality in older breast cancer survivors may be related to an 
increased risk for adverse cardiac outcomes due to treatment related cardiotoxicity31 or 
conversely under-treatment due to lowered functional status, higher prevalence of comorbidities, 
and low life expectancy.32-35 Therefore, the risks and benefits of treatment need to be carefully 
balanced among older women diagnosed with breast cancer and deserves further study. 
 
Our finding that breast cancer survivors overall may have a higher risk of CVD-related mortality 
relative to a comparable group of cancer-free women after 8 years is similar to the previously 
mentioned study by Bradshaw and colleagues conducted among the Long Island Breast Cancer 
Study Project.18 This study observed that CVD mortality increased around 7 years post-diagnosis 
among breast cancer survivors relative to cancer-free women (0-7 years: csHR=0.80, 95% 
CI=0.53-1.2, sdHR=0.59, 95% CI=0.40-0.87; 7+ years: csHR=1.8, 95% CI=1.3-2.5, sdHR=1.9, 
95% CI=1.4-2.7; p-interaction=0.001). Our study adds to this literature by demonstrating that risk 
of CVD-related mortality may be higher among older women and women diagnosed with ER-
positive breast cancer relative to cancer-free women; yet this risk only becomes apparent 8 years 
after diagnosis. However, our results did not significantly differ by time and therefore must be 
interpreted with caution. Additional larger studies are needed to confirm these results.  
 
Although CVD mortality has also been commonly reported in studies among breast cancer 
survivors,5-11 the etiology of CVD mortality among breast cancer survivors is not well 
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understood. Several underlying mechanisms have been proposed, including a higher prevalence 
of CVD risk factors (e.g. older age, obesity, hypertension, diabetes, and physical inactivity) 
among breast cancer survivors36 and cardiotoxic effects from breast cancer treatment (e.g., 
radiation, chemotherapy, hormone therapies, and targeted therapies).37 Adding to the literature, 
our findings may have particularly important clinical implications for women diagnosed at an 
older age or with ER-positive tumors and speak to the importance of potentially implementing 
interventions shortly after diagnosis to reduce risk of CVD death (e.g., monitoring of blood 
pressure, lipid profiles, and weight). This underlies the need for future studies to examine both 
short- and long-term CVD-risk factors and other comorbidities, as well as the effects of treatment 
among these groups.  
 
Strengths of our study include a cancer-free comparison group and the ability to match the 
comparison group on age and time to breast cancer survivors from the same community-based 
cohort. With a cancer-free comparison group, we were able to identify differences in mortality 
between these groups after adjusting for potential confounding factors as well as examine patterns 
of risk (e.g., whether risk differs by time, age or other prognostic factors). Furthermore, follow-up 
time ranged up to 25.9 years and therefore we were able to examine associations between breast 
cancer status and long-term mortality over a long duration of follow-up. 
 
There are several limitations of our study. First, potential confounders were assessed at 
enrollment into the CLUE II cohort in 1989 and the mean time from 1989 to index date was 13.3 
years (SD=7.3 years). However, our results did not change when we adjusted for elapsed time 
from 1989 to the index date to account for potential misclassification of covariates measured 
more distal to the index date. Furthermore, we lacked information on cardiovascular disease and 
complete information on cardiovascular risk factors. However, our results were similar when we 
additionally adjusted for hypertension, hyperlipidemia, and medication use. In addition, we did 
 45 
not have complete information on treatment and therefore were unable to conduct subgroup 
analyses by breast cancer treatment; further studies are needed to examine the effects of treatment 
in breast cancer survivors relative to a cancer-free comparison. Second, it is possible that 
excluding women who developed breast cancer from our reference group may have biased our 
results. However we treated our exposure, breast cancer diagnosis, as a time-varying non-
reversible exposure in a sensitivity analysis and only a small proportion (3%) of women in the 
comparison cohort developed breast cancer after their index date. Overall results were similar to 
our primary analysis in this sensitivity analysis. Third, the underlying cause of death was 
ascertained through death certificates and it is possible that cause of death was misclassified. 
Previous studies have shown that deaths due to heart disease may be overestimated38 and the 
accuracy of cancer deaths may vary by cancer site.39 Although the magnitude of misclassification 
for breast cancer has been shown to be minimal,40,41 we cannot rule out the possibility of 
misclassification in our outcome. Finally, our study consisted of primarily white participants 
(>98%) and results may not be generalizable to women of other racial groups. Future studies are 
needed to examine these associations over time among more diverse populations. 
 
In conclusion, our results show that breast cancer survivors, irrespective of stage and ER-status, 
continue to have higher all-cause mortality due to their disease, compared to their cancer-free 
peers. Further research is needed to understand persistent higher all-cause mortality in breast 
cancer survivors and increased risk over time among elderly breast cancer survivors. Elderly and 
ER-positive breast cancer survivors may also have a higher risk of dying from CVD than cancer-
free women and therefore primary and secondary prevention of CVD may be warranted. Future 
larger prospective cohort studies are needed to confirm these findings. 
 46 
Table 2-1. Participant characteristics in breast cancer survivors and cancer-free women in the 
CLUE II cohort study 
Characteristic Cancer-free women 
(N=3,140) 
Survivors   
(N=628) 
Age at index date, mean years (SD) 64.4 (11.8) 64.5 (11.8) 
Time from enrollment to index date, mean years (SD) 13.3 (7.3) 13.3 (7.3) 
White, % 98.4 99.0 
Education, %     
  <12 years 20.8 18.8 
  12 years 48.5 46.2 
  >12 years 30.7 35.0 
Postmenopausal, % 56.6 58.8 
Body Mass Index, mean kg/m2 (SD) 26.1 (5.1) 26.5 (5.4) 
Body Mass Index, kg/m2,  %     
  <25  48.8 45.1 
  25-<30  30.4 32.5 
  ≥30  20.7 22.5 
  Missing 0.1 0.0 
Smoking status, %     
  Never  61.1 61.8 
  Former 21.4 23.7 
  Current 17.5 14.5 
Alcohol intake, %     
  Never or <1 drink per month 51.4 51.4 
  1-3 drinks per month 12.2 13.1 
  ≥1 drinks per week 32.7 32.2 
  Missing 3.7 3.3 
Oral contraceptive use, %     
  Never 60.8 63.1 
  Former 31.8 29.1 
  Current 6.2 6.7 
  Missing 1.1 1.1 
Hormone use, %     
  Never 80.1 80.1 
  Former 4.2 3.8 
  Current estrogen only 9.1 7.8 
  Current estrogen + progesterone or progesterone only 3.2 4.1 
  Missing 3.4 4.1 
Systolic blood pressure, mean mmHg (SD) 125.9 (35.6) 126.3 (38.6) 
Diastolic blood pressure, mean mmHg (SD) 79.2 (34.1) 79.9 (37.9) 
Plasma total cholesterol, mean mg/dL (SD) 228.0 (119.3) 223.5 (96.8) 
Current high blood pressure medication use, % 19.2 18.6 
Current high cholesterol medication use, % 4.4 3.8 
Current CVD medication use, % 25.0 24.0 
Current diabetes medication use, % 2.1 2.2 
Year of breast cancer diagnosis, median (25th-75th percentile) -- 2002 (1996-2009) 
Breast cancer stage, %     
  I -- 59.7 
  II -- 31.4 
  III -- 7.5 
  Unknown/Missing -- 1.4 
Tumor size (cm), %     
  ≤2 -- 69.1 
  >2  -- 23.4 
  Missing -- 7.3 
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Estrogen receptor status, %     
  Positive -- 73.7 
  Negative -- 16.7 
  Missing -- 9.6 
Abbreviations: CVD, cardiovascular disease  
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Table 2-2. Hazard ratios and 95% confidence intervals for all-cause mortality according to breast 





HR (95% CI)a p-valueb 
Age at diagnosis    
  Age <70 years    
0.10 
    Cancer-free women 242/25,740 1.00 (ref) 
    Breast cancer survivors 92/4,611 2.20 (1.72-2.80) 
  Age ≥70 years   
    Cancer-free women 457/9,597 1.00 (ref) 
    Breast cancer survivors 125/1,660 1.71 (1.42-2.06) 
Time and age      
  Age <70 years      
0.28 
    0-5 years   
      Cancer-free women 44/9,251 1.00 (ref) 
      Breast cancer survivors 29/1,793 3.52 (2.19-5.63) 
    >5-15 years   
      Cancer-free women 125/12,434 1.00 (ref) 
      Breast cancer survivors 40/2,208 1.78 (1.24-2.56) 
    >15 years   
      Cancer-free women 73/3,985 1.00 (ref) 
      Breast cancer survivors 23/662 2.05 (1.28-3.29) 
  Age ≥70 years     
0.05 
    0-5 years   
      Cancer-free women 147/4,648 1.00 (ref) 
      Breast cancer survivors 41/901 1.44 (1.01-2.04) 
    >5-15 years   
      Cancer-free women 246/4,292 1.00 (ref) 
      Breast cancer survivors 70/717 1.76 (1.35-2.30) 
    >15 years   
      Cancer-free women 64/635 1.00 (ref) 
      Breast cancer survivors 14/54 2.69 (1.59-4.55) 
Abbreviations: HR, hazard ratio; CI, confidence interval 
a Adjusted for age (years), menopausal status (premenopausal, postmenopausal), education (<12, 12, >12 
years), smoking status (never, former, current), alcohol intake (0-3 drinks/month, ≥1 drinks/week), body mass 
index (<25, 25-<30, ≥30 kg/m2), oral hormone use (ever, never) using inverse probability weighting 
b P-interaction for the cross-product term of breast cancer status and listed categories 
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Table 2-3. Hazard ratios and 95% confidence intervals for cardiovascular disease-related mortality according to breast cancer status stratified by 
age at diagnosis and the joint association of age at diagnosis and time since diagnosis 
 Deaths/person-
years 
csHR (95% CI)a p-valueb sdHR (95% CI)a p-valueb 
Age at diagnosis      




      Cancer-free women 56/25,740 1.00 (ref) 1.00 (ref) 
      Breast cancer survivors 7/4,611 0.77 (0.35-1.70) 0.68 (0.31-1.49) 
  Age ≥70 years    
      Cancer-free women 149/9,597 1.00 (ref) 1.00 (ref) 
      Breast cancer survivors 37/1,660 1.58 (1.10-2.27) 1.25 (0.87-1.80) 
Time and age      




    0-8 years    
      Cancer-free women 19/13,821 1.00 (ref) 1.00 (ref) 
      Breast cancer survivors 1/2,627 0.35 (0.05-2.60) 0.34 (0.05-2.51) 
    >8 years    
      Cancer-free women 20/7,864 1.00 (ref) 1.00 (ref) 
      Breast cancer survivors 2/1,374 0.53 (0.12-2.26) 0.51 (0.12-2.19) 




    0-8 years    
      Cancer-free women 73/6,577 1.00 (ref) 1.00 (ref) 
      Breast cancer survivors 16/1,248 1.16 (0.67-1.99) 1.10 (0.64-1.88) 
    >8 years    
      Cancer-free women 48/2,364 1.00 (ref) 1.00 (ref) 
      Breast cancer survivors 18/370 2.43 (1.40-4.21) 2.24 (1.29-3.88) 
Abbreviations: csHR, cause-specific hazard ratio; sdHR, subdistribution hazard ratio; CI, confidence interval 
a Adjusted for age (years), menopausal status (premenopausal, postmenopausal), education (<12, 12, >12 years), smoking status (never, former, current), 
alcohol intake (0-3 drinks/month, 1+ drinks/week), body mass index (<25, 25-<30, ≥30 kg/m2), oral hormone use (ever, never) using inverse probability 
weighting 
b P-interaction for the cross-product term of breast cancer status and listed categories 
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Figure 2-1. Proportional mortality ratios in cancer-free women and breast cancer survivors (a) overall and stratified by (b) stage and (c) estrogen-
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Figure 2-2. Proportional mortality ratios in cancer-free women and breast cancer survivors (a-c) overall and restricted to (d-f) stage I tumors and 
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Figure 2-3. Proportional mortality ratios according to breast cancer status stratified by (a-b) age at diagnosis and by time since diagnosis in (c-e) 
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Figure 2-4. Adjusted Kaplan-Meier failure curves and hazard ratios (95% confidence intervals) 
for all-cause mortality in breast cancer survivors compared with cancer-free women. Hazard 
ratios (95% confidence intervals) are presented overall and stratified by time since diagnosis in 
breast cancer survivors compared with cancer-free womena,b 
Abbreviations: PT, person-years; HR, hazard ratio; CI, confidence interval; IPW, inverse probability weighting 
a Adjusted for age, menopausal status, education, smoking status, alcohol intake, body mass index, and oral hormone 
use using IPW 
b The reference group is cancer-free women for all HRs (95% CIs) 
RESULTS 
Acknowledgements: NCI grant T32 CA009314 
Abstract 
number: 
 3271  
  Cancer-free Survivors   
  Events/PT Events/PT HR (95% CI) 
Overall  699/35246 217/6335 1.79 (1.53-2.09) 
Time since diagnosis       
  0-5 years 191/13900 70/2694 1.91 (1.45-2.52) 
  >5-15 years 371/16726 110/2924 1.70 (1.37-2.11) 
  >15 years 137/4620 37/716 1.84 (1.28-2.66) 
  p-interaction     0.91 
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Figure 2-5. Adjusted Kaplan-Meier failure curves and hazard ratios (95% confidence intervals) 
for all-cause mortality in breast cancer survivors stratified by (a) cancer stage and (b) estrogen-
receptor status, compared with cancer-free women. Hazard ratios (95% confidence intervals) are 
presented overall and stratified by time since diagnosis in (a) survivors restricted to stage I cancer 
and (b) survivors restricted to estrogen-receptor positive tumors, compared with cancer-free 
womena,b  
Abbreviations: PT, person-years; HR, hazard ratio; CI, confidence interval; IPW, inverse probability weighting 
a Adjusted for age, menopausal status, education, smoking, alcohol use, body mass index, oral hormone use using IPW 
b The reference group is cancer-free women for all HRs (95% CIs)  
  Cancer-free Survivors 
  Events/PT  Events/PT HR (95% CI) 
Overall     
  Stage I 699/35246 112/3803 1.53 (1.25-1.86) 
  Stage II 699/35246 81/2121 1.94 (1.53-2.47) 
  Stage III 699/35246 22/283 4.86 (3.12-7.56) 
Time since diagnosis among stage I       
  0-5 years 191/13900 28/1615 1.28 (0.86-1.90) 
  >5-15 years 371/16727 61/1766 1.55 (1.18-2.04) 
  >15 years 137/4620 23/418 1.93 (1.24-3.00) 
  p-interaction     0.17 
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  Events/PT  Events/PT HR (95% CI) 
Overall     
  ER-positive 699/35246 158/4614 1.81 (1.52-2.14) 
  ER-negative 699/35246 44/1128 1.98 (1.41-2.76) 
Time since diagnosis among ER-positive       
  0-5 years 191/13,900 45/1993 1.66 (1.20-2.31) 
  >5-15 years 371/16727 84/2114 1.81 (1.42-2.30) 
  >15 years 137/4620 29/507 2.11 (1.42-3.14) 
  p-interaction     0.36 
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Figure 2-6. Adjusted cumulative incidence function and hazard ratios (95% confidence intervals) for 
cardiovascular–related mortality in breast cancer survivors compared with cancer-free women. Hazard 
ratios (95% confidence intervals) are presented overall and stratified by time since diagnosis in breast 
cancer survivors compared with cancer-free womena,b 
Abbreviations: PT, person-years; csHR, cause-specific hazard ratio; sdHR, subdistribution hazard ratio; CI, confidence 
interval; IPW, inverse probability weighting 
a Adjusted for age, menopausal status, education, smoking status, alcohol intake, body mass index, oral hormone use 
using IPW 
b The reference group is cancer-free women for HRs (95% CIs) 
  
RESULTS 
Acknowledgements: NCI grant T32 CA009314 
Abstract 
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  Cancer-free Survivors   
  Events/PT Events/PT csHR (95% CI) sdHR (95% CI) 
Overall  205/35246 44/6335 1.24 (0.89-1.72) 1.09 (0.78-1.51) 
Time since diagnosis         
  0-8 years 92/20398 17/3875 0.99 (0.59-1.66) 0.94 (0.56-1.58) 
  >8 years 68/10228 20/1744 1.71 (1.03-2.83) 1.65 (1.00-2.73) 
  p-interaction     0.14 0.13 
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Figure 2-7. Adjusted cumulative incidence function and hazard ratios (95% confidence intervals) 
for cardiovascular–related mortality in breast cancer survivors stratified by (a) cancer stage and 
(b) estrogen-receptor status, compared with cancer-free women. Hazard ratios (95% confidence 
intervals) are presented overall and stratified by time since diagnosis in (a) survivors restricted to 
stage I cancer and (b) survivors restricted to estrogen-receptor positive tumors, compared with 
cancer-free womena,b  
Abbreviations: PT, person-years; HR, hazard ratio; CI, confidence interval; IPW, inverse probability weighting 
a Adjusted for age, menopausal status, education, smoking, alcohol use, body mass index, oral hormone use using IPW 
b The reference group is cancer-free women for all HRs (95% CIs)  
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  >8 years 68/10228 16/1246 1.92 (1.11-3.33) 1.85 (1.06-3.20) 
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The following tables display information and results that were conducted to supplement Chapter 
2.  
 
Appendix 2-1 shows vital status characteristics as of December 31, 2015 by breast cancer status. 
There were a total of 916 deaths (699 in cancer-free women, 217 in breast cancer survivors). 
Breast cancer survivors were more likely to experience death from any cause compared to cancer-
free women (34.6% vs. 22.3%). Deaths from cardiovascular disease were similar among breast 
cancer survivors compared to cancer-free women (7% vs. 6.5%). 
 
Appendix 2-2 presents the list of International Disease Classification (ICD) codes used for the 
determination of cause-specific mortality. Among 916 deaths, 27.3% were CVD-related deaths, 
which were primarily due to ischemic heart disease, and 22.6% were cancer-related deaths. Other 
CVD-related deaths, which were not included in our primary outcome were cerebrovascular 
(7.2%) and essential hypertension/ hypertensive renal disease (2.3%).   
 
Appendix 2-3 shows the HRs and 95% CIs for all-cause, CVD-related, and non-CVD-related 
mortality according to breast cancer status for age- and multivariable-adjusted models. Overall, 
results were similar in age- and multivariable-adjusted models. Here we also observed that non-
CVD mortality was higher among breast cancer survivors relative to cancer-free women 
(csHR=2.01; 95% CI=1.69-2.40). Results using competing risk regression were similar 
(sdHR=1.98; 95% CI=1.66-2.36).  
 
Appendix 2-4 presents multivariable adjusted HRs and 95% CIs for CVD-related mortality and 
non-CVD mortality stratified by stage and ER-status. The hazard of non-CVD mortality in breast 
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cancer survivors relative to cancer-free women increased with increasing stage (stage I: 
csHR=1.59, 95% CI=1.26-2.01; stage II: csHR=2.30, 95% CI=1.77-2.99; stage III: csHR=6.42, 
95% CI=3.98-10.33). For ER-status, both women with ER-positive and ER-negative breast 
cancer had higher non-CVD morality relative to cancer-free women (ER-positive: csHR=1.97, 
95% CI=1.61-2.40; ER-negative: csHR=2.48, 95% CI=1.73-3.54). Results were similar using 
competing risk regression. 
 
Appendix 2-5 shows multivariable adjusted HRs and 95% CIs for CVD-related mortality and 
non-CVD mortality stratified by time since index date. Results are presented overall and 
restricted to stage I and ER-positive breast cancer survivors. The HR for non-CVD mortality was 
over 2-fold in the first 8 years but becomes attenuated after 8 years (0-8 years: csHR=2.37, 95% 
CI=1.85-3.03; >8 years: csHR=1.51, 95% CI=1.11-2.07; p-interaction=0.03). Results for non-
CVD mortality did not differ by time in analyses restricted to stage I breast cancer compared to 
cancer-free women. (0-8 years: csHR=1.42, 95% CI=0.99-2.05; >8 years: csHR=1.54, 95% 
CI=1.05-2.26; p-interaction=0.78). Analyses restricted to ER-positive survivors compared to 
cancer-free women indicated that women with ER-positive breast cancer had higher non-CVD 
mortality in the first 8 years and results become attenuated after 8 years (0-8 years: csHR=2.13, 
95% CI=1.60-2.83; >8 years: csHR=1.59, 95% CI=1.12-2.27; p-interaction=0.21). Results for 
these analyses were similar using competing risk regression. 
 
 
Appendix 2-6 presents multivariable adjusted HRs and 95% CIs for CVD-related mortality and 
non-CVD mortality stratified by age at index date and jointly by age and then time since index 
date. Among women <70 years at index date, breast cancer survivors had higher non-CVD 
mortality compared to cancer-free women (csHR=2.63, 95% CI=2.02-3.41) and results are 
attenuated among women ≥70 years at index date (csHR=1.78, 95% CI=1.42-2.23). Among 
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women aged <70 years at index date, breast cancer survivors had an over 4-fold higher hazard of 
non-CVD mortality compared to cancer-free women in the first 8 years and results were 
attenuated after 8 years (0-8 years: csHR=4.16, 95% CI=2.81-6.16; >8 years: csHR=1.64, 95% 
CI=1.00-2.68; p-interaction=0.004). Among women aged ≥70, non-CVD mortality did not differ 
by time (0-8 years: csHR=1.69, 95% CI=1.22-2.35; >8 years: csHR=1.55, 95% CI=1.04-2.31; p-
interaction=0.74). Results were overall similar with competing risk regression. 
 
Appendix 2-7 shows comparisons for alternate analytic methods. Results using cox proportional 
hazards regression stratified by an indicator for matched set were similar to results from our 
primary approach (all-cause mortality: HR=1.83, 95% CI=1.58-2.11; CVD-related mortality: 
HR=1.24, 95% CI=0.92-1.69). Results using breast cancer as a time-varying exposure were also 
similar to results in our primary approach (All-cause mortality: HR=1.73, 95% CI=1.49-2.02; 
CVD-related mortality: HR=1.22, 95% CI=0.88-1.71).
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Appendix 2-1. Vital status characteristics as of December 31, 2015 by breast cancer status 
Vital status Cancer-free women 
(N=3,140) 
Breast cancer survivors 
(N=628) 
Death from any cause, n (%)     
  Overall 699 (22.3) 217 (34.6) 
  <70 242 (11.8) 92 (22.5) 
  ≥70 637 (41.8) 125 (57.1) 
Death from breast cancer, n (%) 0 (0.0) 64 (10.2) 
Death from cancer (non-breast cancer), n (%) 111 (3.5) 25 (4.0) 




Appendix 2-2. List of International Classification of Disease (ICD) codes used for determination 
of cause-specific mortality (Total deaths=916) 
 ICD codes N % 
Cardiovascular disease related deaths  249 27.3 
  Rheumatic disease 390-398, I00-I09 3 0.003 
  Hypertensive diseases 402, 404, I11, I13 18 2.0 
  Ischemic heart disease  410-414, I20-I25 172 18.8 
  Pulmonary heart disease 415-417, I26-I28 8 0.01 
  Other forms of heart disease 420-429, I30-I51 48 5.2 
Other cardiovascular disease    
  Cerebrovascular 430-438, I60-I69 66 7.2 
  Essential hypertension, hypertensive renal    
  disease 
401,404, 405,I10, I12, I15 21 2.3 
Cancer  140-208, C00-C097 207 22.6 
Dementia 290, F03, G30,  86 9.4 
Infection  480-487, J10-J18, 038, A40-A41 43 4.7 
Diabetes 250, E10-E14 43 4.7 
Pulmonary disease 490-493, 496, J40-J47 73 8.0 
Deaths from all other causes All other codes 128 14.0 
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Appendix 2-3. Comparison of hazard ratios (95% confidence intervals) for all-cause, cardiovascular disease, and non-cardiovascular disease 
mortality according to breast cancer status 






















Age-adjusted HR (95% CI)a 1.00 (ref) 1.76 (1.51-2.06) 1.00 (ref) 1.22 (0.88-1.69) 1.00 (ref) 1.99 (1.67-2.37) 
MV-adjusted HR (95% CI)b 1.00 (ref) 1.79 (1.53-2.09) 1.00 (ref) 1.24 (0.89-1.72) 1.00 (ref) 2.01 (1.69-2.40) 
Extended MV-adjusted HR (95% CI)c 1.00 (ref) 1.80 (1.54-2.10) 1.00 (ref) 1.26 (0.91-1.75) 1.00 (ref) 2.02 (1.69-2.41) 
Competing risk regression       
Age-adjusted sdHR (95% CI)a -- -- 1.00 (ref) 1.07 (0.77-1.48) 1.00 (ref) 1.96 (1.65-2.33) 
MV-adjusted sdHR (95% CI)b -- -- 1.00 (ref) 1.09 (0.78-1.51) 1.00 (ref) 1.98 (1.66-2.36) 
Extended MV-adjusted sdHR (95% CI)c -- -- 1.00 (ref) 1.10 (0.80-1.53) 1.00 (ref) 1.98 (1.66-2.36) 
Abbreviations: CVD, cardiovascular disease; BC, breast cancer; MV, multivariable; sdHR, subdistribution hazard ratio 
Models are adjusted for covariates using inverse probability weighting 
a Adjusted for age (years) 
b Adjusted for age (years), menopausal status (premenopausal, postmenopausal), education (<12, 12, >12 years), smoking status (never, former, current), alcohol intake 
(0-3 drinks/month, ≥1 drinks/week), body mass index (<25, 25-<30,≥30 kg/m2), oral hormone use (ever, never) 
c Adjusted for age (years), menopausal status (premenopausal, postmenopausal), education (<12, 12, >12 years), smoking status (never, former, current), alcohol intake (0-
3 drinks/month, ≥1 drinks/week), body mass index (<25, 25-<30, ≥30 kg/m2), oral hormone use (ever, never), high blood pressure (yes, no), high cholesterol (yes, no), 




Appendix 2-4. Hazard ratios (95% confidence intervals) for cardiovascular disease and non-cardiovascular disease mortality in breast cancer 
survivors stratified by tumor characteristics compared to cancer-free women 
  CVD mortality Non-CVD mortality 
  Deaths/person-years csHR (95% CI)a,b sdHR (95% CI)a,b Deaths/person-years csHR (95% CI)a,b sdHR (95% CI)a,b 








Stage at diagnosis         
Stage I 205/35,246 29/3,750 1.37 (0.93-2.02) 1.27 (0.86-1.87) 494/35,246  83/3,803 1.59 (1.26-2.01) 1.55 (1.23-1.96) 
Stage II 205/35,246 13/2,121 1.08 (0.62-1.90) 0.93 (0.53-1.63) 494/35,246  67/2,130 2.30 (1.77-2.99) 2.28 (1.76-2.97) 
Stage III 205/35,246 2/283 1.33 (0.33-5.32) 0.74 (0.18-2.98) 494/35,246  20/280 6.42 (3.98-10.33) 6.01 (3.69-9.80) 
ER-status                 
ER-positive 205/35,246 37/4,539 1.45 (1.02-2.06) 1.28 (0.90-1.82) 494/35,246 121/4,614 1.97 (1.61-2.40) 1.91 (1.56-2.33) 
ER-negative 205/35,246 5/1,122 0.76 (0.31-1.87) 0.63 (0.26-1.54) 494/35,246  39/1,128 2.48 (1.73-3.54) 2.51 (1.80-3.58) 
Abbreviations: CVD, cardiovascular disease; BC, breast cancer; csHR, cause-specific hazard ratio; sdHR, subdistribution hazard ratio 
a The reference group for all models is cancer-free women 
b Adjusted for age (years), menopausal status (premenopausal, postmenopausal), education (<12, 12, >12 years), smoking status (never, former, current), alcohol intake (0-3 




Appendix 2-5. Hazard ratios (95% confidence intervals) for cardiovascular disease and non-cardiovascular disease mortality according to breast 
cancer status stratified by time since diagnosis 
Time since 
diagnosis 
CVD mortality Non-CVD mortality 









Overall         
0-8 years 92/20,398 17/3,875 0.99 (0.59-1.66) 0.94 (0.56-1.58) 210/20,398 93/3,875 2.37 (1.85-3.03) 2.36 (1.85-3.02) 
>8 years 68/10,228 20/1,744 1.71 (1.03-2.83) 1.65 (1.00-2.73) 192/10,228 50/1,744 1.51 (1.11-2.07) 1.48 (1.09-2.03) 
p-interactionc   0.14 0.13   0.03 0.02 
Stage I                  
0-8 years 92/20,398 12/2,327 1.18 (0.64-2.16) 1.16 (0.63-2.12) 210/20,425 34/2,311 1.42 (0.99-2.05) 1.42 (0.98-2.04) 
>8 years 68/10,228 12/1,054 1.68 (0.90-3.13) 1.61 (0.87-3.00) 192/10,264 31/1,030 1.54 (1.05-2.26) 1.52 (1.03-2.23) 
p-interactionc   0.42 0.45     0.78 0.8 
ER-positive          
0-8 years 92/20,398 14/2,861 1.10 (0.62-1.93) 1.06 (0.60-1.86) 210/20,425 62/2,838 2.13 (1.60-2.83) 2.13 (1.60-2.83) 
>8 years 68/10,228 16/1,246 1.92 (1.11-3.33) 1.85 (1.06-3.20) 192/10,264 37/1,217 1.59 (1.12-2.27) 1.55 (1.09-2.21) 
p-interactionc   0.17 0.17     0.21 0.17 
Abbreviations: CVD, cardiovascular disease; BC, breast cancer; csHR, cause-specific hazard ratio; sdHR, subdistribution hazard ratio; ER, estrogen-receptor 
a The reference group for all models is cancer-free women 
b Adjusted for age (years), menopausal status (premenopausal, postmenopausal), education (<12, 12, >12 years), smoking status (never, former, current), alcohol intake 
(0-3 drinks/month, ≥1 drinks/week), body mass index (<25, 25-<30, ≥30 kg/m2), oral hormone use (ever, never) using inverse probability weighting 






Appendix 2-6. Hazard ratios (95% confidence intervals) for cardiovascular disease and non-cardiovascular disease mortality according to breast 
cancer status stratified by age at diagnosis and the joint association of age at diagnosis and time since diagnosis 
  CVD mortality Non-CVD mortality 
 Deaths/person-years csHR (95% CI)a,b sdHR (95% CI)a,b Deaths/person-years csHR (95% CI)a,b sdHR (95% CI)a,b 








Age at diagnosis         
Age <70 years 56/25,740 7/4,611 0.77 (0.35-1.70) 0.68 (0.31-1.49) 186/25,670 85/4662 2.63 (2.02-3.41) 2.64 (2.03-3.43) 
Age ≥70 years 149/9,597 37/1,660 1.58 (1.10-2.27) 1.25 (0.87-1.80) 308/9,576 88/1672 1.78 (1.42-2.23) 1.59 (1.26-2.00) 
p-interactionc   0.11 0.18   0.01 0.01 
Time and age         
Age <70 years         
  0-8 years 19/13,821 1/2,627 0.35 (0.05-2.6) 0.34 (0.05-2.51) 58/13,821 45/2627 4.16 (2.81-6.16) 4.16 (2.81-6.16) 
  >8 years 20/7,864 2/1,374 0.53 (0.12-2.26) 0.51 (0.12-2.19) 72/7,864 21/1374 1.64 (1.00-2.68) 1.65 (1.01-2.70) 
  p-interactionc   0.75 0.74   0.004 0.004 
Age ≥70 years         
   0-8 years 73/6,577 16/1,248 1.16 (0.67-1.98) 1.10 (0.64-1.88) 152/6,577 48/1248 1.69 (1.22-2.35) 1.67 (1.20-2.31) 
  >8 years 48/2,364 18/370 2.43 (1.40-4.21) 2.24 (1.29-3.88) 120/2,364 29/370 1.55 (1.04-2.31) 1.40 (0.94-2.09) 
  p-interactionc   0.06 0.07   0.74 0.48 
Abbreviations: CVD, cardiovascular disease; BC, breast cancer; csHR, cause-specific hazard ratio; sdHR, subdistribution hazard ratio 
a The reference group for all models is cancer-free women 
b Adjusted for age (years), menopausal status (premenopausal, postmenopausal), education (<12, 12, >12 years), smoking status (never, former, current), alcohol intake (0-3 
drinks/month, ≥1 drinks/week), body mass index (<25, 25-<30, ≥30 kg/m2), oral hormone use (ever, never) using inverse probability weighting 






Appendix 2-7. Comparison of hazard ratios (95% confidence intervals) for all-cause and 
cardiovascular disease mortality according to breast cancer status using alternative analytic 
approaches 















Model A HR (95% CI)a,b 1.00 (ref) 1.83 (1.58-2.11) 1.00 (ref) 1.24 (0.92-1.69) 
Model B HR (95% CI)a,c 1.00 (ref) 1.73 (1.49-2.02) 1.00 (ref) 1.22 (0.88-1.71) 
Abbreviations: CVD, cardiovascular disease; BC, breast cancer 
a Adjusted for age (years), menopausal status (premenopausal, postmenopausal), education (<12, 12, >12 years), 
smoking status (never, former, current), alcohol intake (0-3 drinks/month, ≥1 drinks/week), body mass index (<25, 
25-<30, ≥30 kg/m2), oral hormone use (ever, never) using inverse probability weighting 
b Models are stratified by matched set 







Chapter 3.  
 
Incident cardiovascular disease risk factors in breast cancer survivors compared to 









Background: Cardiovascular disease (CVD) morbidity and mortality is an issue of increasing 
concern among breast cancer survivors. Several modifiable risk factors including hypertension, 
elevated blood lipids, and diabetes have been commonly reported in breast cancer survivors and 
may represent a crucial early point of intervention to improve long-term CVD health. However, 
whether breast cancer survivors have an increased risk of incident CVD risk factors relative to 
cancer-free women and whether these risk factors develop shortly after diagnosis remains 
unknown.  
 
Methods: We prospectively examined the incidence of hypertension, high cholesterol, high 
triglycerides, and diabetes in breast cancer survivors compared to cancer-free women in the 
Breast and Ovarian Surveillance Service (BOSS) study, an ongoing familial risk cohort. 
Survivors were diagnosed with ductal carcinoma in situ or stage I-IV breast cancer ≤5 years prior 
to baseline (N=304). Cancer free women were defined as women with no prior history of cancer 
at baseline (except non-melanoma skin cancer or cervical carcinoma in situ) (N=742). Breast 
cancer and tumor characteristics were confirmed with pathology records. Incident CVD risk 
factors were ascertained based on self-reported physician diagnosis. Multivariable hazard ratios 
(HR) and 95% confidence intervals (CI) for CVD risk factors were calculated using Cox 
proportional hazard regression models.  
 
Results: Breast cancer survivors were diagnosed, on average, 1.4 years prior to study enrollment 
and the mean age at diagnosis ranged from 47-49 years. Overall, in multivariable models, breast 
cancer survivors did not have a higher risk of hypertension, high cholesterol, or diabetes. An 
increased risk of developing high triglycerides was observed in breast cancer survivors relative to 
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cancer free women (HR=3.96, 95% CI=1.85-8.51) and, although not significant, there was a 
suggestion that risk of high triglycerides may differ by BMI subgroups (p-interaction=0.10). Risk 
of hypertension was increased in breast cancer survivors diagnosed at age ≤50 relative to cancer-
free women (HR=2.04, 95% CI=1.04-4.00), although no association was observed in survivors 
diagnosed at age >50 years compared to cancer-free women (HR=0.76, 95% CI=0.33-1.77). 
 
Conclusion: Our study suggests that closer monitoring of triglyceride levels among all breast 







Cardiovascular disease (CVD) is an established long-term risk after breast cancer1 and represents 
the leading cause of non-cancer death among breast cancer survivors in the United States.2 
Several modifiable risk factors including hypertension, elevated blood lipids, and diabetes have 
been commonly reported in breast cancer survivors and may represent a crucial point for early 
intervention to reduce the long-term risk of CVD.3 However, the development of CVD risk 
factors in breast cancer survivors is likely multifactorial as it is related to both breast cancer and 
its treatment as well as age, menopausal status, and lifestyle factors (e.g., obesity and physical 
inactivity).4,5   
 
Among breast cancer survivors, the direct effects of treatment on CVD risk have been well 
established (e.g., radiation induced cardiovascular injury and cardiotoxic effects of systemic 
therapies).3,6 In addition, breast cancer treatment has been linked to small yet unfavorable changes 
in blood pressure6-11 and blood lipids,12-16 and an increased risk of diabetes.3,17 Treatment-related 
early menopause, which lowers endogenous estrogen levels, may also increase weight gain and 
subsequently lead to unfavorable metabolic changes.1 Importantly, hypertension, elevated blood 
lipids, and diabetes are also prevalent in cancer-free women due to factors such as obesity, 
unhealthy diet, physical inactivity, and family history.18 Therefore, these factors may also 
contribute to the development of CVD in breast cancer survivors in addition to treatment related 
effects.  
 
Several prior studies have reported a higher prevalence of CVD risk factors in long-term breast 
cancer survivors relative to cancer-free women19,20 and one study has reported that adolescent and 
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young adult breast cancer survivors are more likely to develop CVD risk factors compared to 
cancer-free individuals.21 However, to our knowledge, no prior study has examined incident CVD 
risk factors in adult breast cancer survivors compared to cancer-free women. Therefore, it 
remains unclear whether breast cancer survivors, particularly those that are recently diagnosed, 
are more likely to develop CVD risk factors than their cancer-free peers and to what degree age, 
menopause, and lifestyle factors confound this association.  
 
To examine the risk of hypertension, high cholesterol, high triglycerides, and diabetes in recently 
diagnosed breast cancer survivors compared to cancer-free women, we analyzed data from 







The Breast and Ovarian Surveillance Service (BOSS) study is an ongoing prospective cohort 
study, which recruited women and men with familial risk for breast and/or ovarian cancer in 
2005-2013 from the cancer genetics clinic at the John Hopkins Sidney Kimmel Comprehensive 
Cancer Center in Baltimore, Maryland. Eligible participants were aged ≥18 years with either: 1) a 
family history of breast and/or ovarian cancer, 2) a documented BRCA1/2 mutation, 3) a 
diagnosis with breast cancer at ≤40 years of age without a family history of breast cancer, or 4) a 
diagnosis with ovarian cancer at any age without a family history of ovarian cancer. At baseline, 
participants completed a detailed questionnaire to collect information on a variety of 
demographic, lifestyle, and health factors including information on medical history and breast 
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cancer treatment. Participants have updated their information every 3-4 years thereafter with 
follow-up questionnaires (>92% have completed at least 1 follow-up questionnaire). 
 
For the present analysis, women were included if they completed a baseline questionnaire and at 
least 1 follow-up questionnaire through December 31st, 2017 (n=1,178). Breast cancer survivors 
were defined as women diagnosed with breast cancer (ductal carcinoma in situ or stage I-IV 
breast cancer) within 5 years prior to enrollment (n=304). The comparison group was restricted to 
women with no prior history of cancer at baseline except non-melanoma skin cancer or cervical 
carcinoma in situ (N=742). Women who reported a physician diagnosis for hypertension, high 
cholesterol, high triglycerides, or diabetes at baseline were excluded from analyses for that risk 
factor. We further excluded women with missing responses on baseline or follow-up 
questionnaires from analyses for that risk factor (n=3 for hypertension; n=3 for high cholesterol; 
n=7 for high triglycerides; n=1 for diabetes). After these exclusions, our analytic populations 
ranged from 675 to 922 women. 
 
Ascertainment of breast cancer and treatment 
 
Breast cancer was self-reported at enrollment and pathology records were used to confirm all 
diagnoses (International Classification of Disease-10 code: invasive breast cancer [C50]; ductal 
carcinoma in situ [D05.1] and lobular carcinoma in situ [D05.0]). Breast cancer stage and subtype 
(estrogen/progesterone receptor and HER2 status) was also confirmed with pathology reports. 
Breast cancer treatment was ascertained in baseline questionnaires and confirmed with medical 
record review (99% confirmed for the present analysis). Treatment information included surgery 




Ascertainment of CVD risk factors  
 
Physician diagnosed CVD risk factors including high blood pressure (excluding during 
pregnancy), high cholesterol, high triglycerides, and diabetes were ascertained in baseline and 
follow-up questionnaires. In each questionnaire, participants were asked to indicate whether they 
had received a physician’s diagnosis and the date of diagnosis. Incident cases of hypertension, 
high cholesterol, high triglycerides and diabetes were identified on follow-up questionnaires. We 
did not include weight gain as a CVD risk factor in this analysis since it was previously 
established in this cohort that weight gain was higher in cancer survivors relative to cancer-free 
women.22 
 
Ascertainment of covariates 
 
Information on covariates [age, race, education level, menopausal status, age at menopause, 
oophorectomy at a young age, body mass index (BMI), physical activity based on metabolic 
equivalents of task (METs) per week, alcohol intake, smoking status, hormonal replacement 
therapy (HRT) use, and history of screening (mammography, pap smear)] was collected from the 
baseline questionnaire. Removal of the ovaries was based on self-report and confirmation with 
pathology records is ongoing. We defined a bilateral oophorectomy at a young age as the removal 




We calculated age-adjusted means and proportions for baseline characteristics in breast cancer 
survivors and cancer-free women using regression modeling. We used Cox proportional hazard 
models to estimate age- and multivariable-adjusted hazard ratios (HRs) of incident CVD risk 
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factors with 95% confidence intervals (CIs). We used age as the time scale in our models.23 
Women contributed person-time from the completion date of the baseline questionnaire to the 
date of diagnosis for a CVD risk factor or until end of last follow-up through December 31st, 
2017, whichever occurred first. The proportional hazards assumption between all covariates and 
CVD risk factors was assessed with Schoenfeld residuals and indicated that the assumption of 
proportional hazards was not violated. We identified confounders a priori as variables that may 
be associated with both breast cancer incidence and CVD risk factors. Our primary multivariable 
model adjusted for race (white, other), education status (<4 years of college, ≥4 years of college), 
menopausal status (premenopausal, postmenopausal), hormone replacement therapy (ever, never), 
body mass index (BMI) (kg/m2), physical activity (MET-h/week), smoking status (ever, never) 
and alcohol use (g/day). A second multivariable model mutually adjusted for the other CVD risk 
factors to examine the independent effect of each CVD risk factor. Overall, results were similar 
between these two models, therefore we discuss model results from the more parsimonious model 
that did not mutually adjust for other CVD risk factors. Due to a small percent of missing values 
for covariates included in multivariable models (<1% missing), we imputed missing data with the 
most common category for categorical covariates and the median value for continuous covariates 
among cancer-free women.  
 
We conducted a number of sensitivity analyses. First, we excluded women diagnosed with stage 0 
or stage IV breast cancer from our primary analyses since treatment may differ in these groups 
compared to women with stage I-III breast cancer. Second, we excluded women with an early 
bilateral oophorectomy prior to baseline. We excluded these women since early bilateral 
oophorectomy is associated with CVD mortality and therefore women still alive and healthy at 
baseline may represent a unique population. Finally, we excluded women with a change in 
menopause over follow-up to determine if menopause, either natural or treatment-related, might 
be driving the development of incident CVD risk factors.  
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We further examined the risk of hypertension, high cholesterol, and high triglycerides in women 
with breast cancer stratified by age at diagnosis, menopausal status at diagnosis, and estrogen-
receptor (ER) tumor status to determine if the association may differ by these factors. Models that 
stratified survivors by ER-status were restricted to invasive cancer since this information has not 
been routinely measured, until recently, in women with in situ breast cancer. We were unable to 
examine incident diabetes for these subgroup analyses and the effects of breast cancer treatment 
on the development of CVD risk factors due to small numbers. Finally, we conducted stratified 
analyses to determine whether associations between breast cancer status and incident CVD risk 
factors differed by baseline BMI. Heterogeneity was tested using the likelihood ratio test. 
 
Analyses were conducted using SAS version 9.4 (SAS Institute Inc., Cary, NC, USA) and Stata 
version 14.0 (StataCorp LP, College Station, TX, USA). All statistical tests were two-side and P 




Table 3-1 describes age and age-adjusted characteristics at baseline for each analytic population 
according to breast cancer status. Overall, characteristics were similar among breast cancer 
survivors compared to cancer-free women. However, breast cancer survivors tended to be older 
and postmenopausal and were less likely to be white compared to cancer-free women. In addition, 
both groups were highly educated with approximately 80% of women with ≥4-years of college. 
Among breast cancer survivors, the mean time from diagnosis to enrollment was 1.4 years and 
the mean age at diagnosis ranged from 47-49 years. Breast cancer survivors were primarily 
diagnosed with invasive breast cancer and ER-positive breast tumors. For breast cancer treatment, 
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all survivors received surgery (excluding women with stage IV breast cancer) and approximately 
50% received chemotherapy. In addition, over 65% of breast cancer survivors received any 
hormone therapy.  
 
Table 3-2 describes risk of hypertension, elevated blood lipids, and diabetes among breast cancer 
survivors relative to cancer-free women. Breast cancer status was not significantly associated 
with incident hypertension, high cholesterol, and diabetes. However, risk of high triglycerides 
was almost 4-fold higher in breast cancer survivors relative to cancer-free women (HR=3.96, 
95% CI=1.85-8.51). Results were similar in models that mutually adjusted for other CVD risk 
factors. In sensitivity analyses, we excluded women with stage 0 or stage IV breast cancer from 
our models and overall results were comparable to our primary analyses. Results that excluded 
women with an early bilateral oophorectomy were also generally similar to our primary analyses; 
however, the magnitude of risk for incident high triglycerides was even stronger in this model. 
Results that excluded women with a change in menopause over follow-up were attenuated 
suggesting that becoming post-menopausal may play a role in the development of CVD risk 
factors. However, results for incident high triglycerides remained statistically significant 
suggesting that other factors may also play a role in the development of this risk factor (HR=2.74, 
95% CI=1.13-6.63).  
 
Table 3-3 examines CVD risk factors in breast cancer survivors stratified by age at diagnosis, 
menopausal status at diagnosis, and ER-status compared to cancer-free women. Overall, women 
diagnosed at a younger age had a higher risk of hypertension compared to cancer-free women. 
Specifically, women diagnosed with breast cancer at age ≤50 years had a 2-fold increased risk of 
hypertension compared to cancer-free women (HR=2.04; 95% CI=1.04-4.00). No increased risk 
of hypertension was observed in survivors diagnosed at age >50 years compared to cancer-free 
women (HR=0.76, 95% CI=0.33-1.77). In addition, risk of high triglycerides remained increased 
 80 
among breast cancer survivors relative to cancer-free women in all models and did not differ by 
age or menopausal status at diagnosis. Risk of elevated triglycerides was over 7-fold higher 
among women with ER-negative breast cancer and over 3-fold higher among women with ER-
positive tumors (HR=7.61, 95% CI=2.50-23.17, HR=3.29, 95% CI=1.34-8.07, respectively).  
 
We then examined the findings by subgroups of BMI at baseline (BMI<25 kg/m2, BMI≥25 
kg/m2) (Table 3-4). Results did not differ by BMI status for incident hypertension and high 
cholesterol. However, there was a suggestion that risk of high triglycerides differed by baseline 
BMI status (p-interaction=0.10). Specifically, women with breast cancer had an almost 8-fold and 
over 2-fold increased risk of high triglycerides relative to cancer-free women among 
overweight/obese women and normal weight women, respectively (HR=7.88, 95% CI=2.61-




In this prospective study, we observed an increased risk of high triglycerides in breast cancer 
survivors relative to cancer-free women particularly among overweight/obese women. We found 
no overall association between breast cancer status and incident hypertension, high cholesterol, or 
diabetes. However, we observed that women diagnosed with breast cancer at age ≤50 years may 
have an increased risk of hypertension compared to cancer-free women. These findings highlight 
the need to mitigate CVD risk factors early after diagnosis to reduce the long-term risk of CVD in 
breast cancer survivors.  
 
Although several studies have reported a higher prevalence of CVD risk factors in breast cancer 
survivors compared to cancer-free women,19,20 this study is the first, to our knowledge, to 
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examine incident CVD risk factors in adult breast cancer survivors compared to cancer-free 
women. One previous study examined incident CVD risk factors, as well as incident CVD, 
among adolescent and young adult (AYA) cancer survivors (aged 15-39 years at diagnosis; 
n=963 breast cancer survivors) compared to an age- and sex-matched group without cancer 
(n=57,617) in the Kaiser health care system.21 After 4.1 mean years of follow-up, this study found 
that breast cancer survivors had a higher incidence of diabetes and dyslipidemia compared to 
cancer-free women after adjusting for age, ethnicity, smoking, and BMI (IRR=1.55, 95% 
CI=1.20-2.02; IRR=1.20, 95% CI=1.01-1.43, respectively). This study found no association 
between breast cancer status and hypertension (IRR=1.06; 95% CI=0.86-1.32). Our study was 
conducted among adult breast cancer survivors (mean age at diagnosis=47-49 years) and 
therefore there may be important differences in breast cancer characteristics (i.e., stage and tumor 
subtype) and thus subsequent treatment compared to the Kaiser population of AYA survivors. 
The authors did not report clinical cancer information on stage, subtype, or treatment; therefore it 
is hard to determine if this may be driving the differences in results between studies. Furthermore, 
risk of hypertension, high blood lipids, and diabetes may differ substantially among adult women 
compared to AYA women since development of these factors is also highly associated with 
increasing age and menopausal status. In addition, we analyzed high cholesterol and triglycerides 
as individual outcomes and it is unclear if high triglycerides were included in the composite 
outcome of dyslipidemia in the Kaiser study. It is also possible that our analyses were 
underpowered to detect the modest association with diabetes that was observed in the Kaiser 
population of AYA survivors.  
 
We are the first prospective study to report that breast cancer survivors may have an increased 
risk of high triglycerides compared to cancer-free women after accounting for the effects of age 
and menopause, which are strong confounders. Furthermore, this association persisted after 
adjustment for other CVD risk factors including hypertension, diabetes, and high cholesterol and 
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in additional sensitivity analyses. This suggests that the underlying etiology may be related to 
breast cancer and its treatment. Although tamoxifen has been shown to decrease total and low-
density lipoprotein (LDL) cholesterol levels,24,25 previous clinical studies have also shown that 
tamoxifen use may increase serum triglycerides.12,13 While the mechanisms underlying this 
association are unknown, it is hypothesized that estrogen may be protective and therefore 
lowering tamoxifen dosage may reduce the risk of hypertriglyceridemia.13 Future studies are 
needed to confirm if tamoxifen use or other breast cancer treatments may be driving the increased 
risk of high triglycerides among breast cancer survivors relative to cancer-free women and 
whether there is a long-term increased risk. Further studies are also needed to confirm our finding 
that the elevation in triglycerides may be greater in overweight/obese women. 
 
We are also the first study to find that breast cancer survivors diagnosed at age ≤50 years (mean 
age at diagnosis=42 years) had a higher risk of hypertension compared to cancer-free women. 
Although this finding needs to be confirmed with repeated measurements and in larger studies, it 
is possible that this increased risk may be due to either direct or indirect effects of treatment. 
Hypertension has been commonly reported in breast cancer patients treated with selected 
angiogenesis inhibitors.6,26-28 Specifically, Bevacizumab, an angiogenesis inhibitor that was 
approved for the treatment of metastatic HER2-negative breast cancer from 2008-2011, has been 
associated with an increased risk of hypertension.8,28 However, this is unlikely to explain the 
observed association in our analysis since only 2 women diagnosed at age ≤50 years had this 
treatment and neither developed incident hypertension. It is also possible that women diagnosed 
at a younger age may be more likely to receive chemotherapy due to aggressive tumor biology 
associated with a younger age at diagnosis. Indeed, in this analysis, women diagnosed at ≤50 
years were slightly more likely to receive chemotherapy compared to women diagnosed at >50 
years (52% vs. 45%, respectively). Chemotherapy, particularly anthracyclines and cisplatin, has 
been shown to cause vascular endothelial damage, and has been associated with hypertension in 
 83 
cancer patients.7,26,29 Further work is ongoing to determine if younger women in our study were 
more likely to receive anthracycline chemotherapy agents. In addition, chemotherapy can induce 
treatment-related early menopause and lower levels of endogenous estrogen may subsequently 
cause unfavorable changes in blood pressure and increases in weight gain, which may also play a 
role in the development of hypertension.1  
 
The strengths of this study include the prospective design and a direct comparison to cancer-free 
women from the same cohort. However, our study also has several limitations. First, our sample 
size was limited and our analyses were underpowered to detect significant small to moderate 
associations. We were also unable to examine treatment effects due to our limited sample size. 
However, we are the first study to examine incident CVD risk factors in adult breast cancer 
survivors relative to cancer-free women within the same cohort. Larger studies are needed to 
replicate our findings and to examine treatment effects. Second, incident CVD risk factors were 
based on self-reported physician diagnosis, therefore we can not rule out the potential for 
outcome misclassifiction. However, women in the BOSS cohort are at high risk for familail breast 
cancer and thus both breast cancer survivors and cancer-free women routinely undergo health 
assessments. In addition, health screening exams reported at baseline were similar by breast 
cancer status and therefore it is unlikely that self-reported outcomes might differ by exposure 
group. Third, our results may lack generalizability to other populations since our study population 
was comprised of predominately white and highly-educated women with a family history of 
breast cancer. Future studies are needed in other diverse study populations.  
 
In conclusion, breast cancer survivors had an increased risk of high triglycerides relative to 
cancer-free women and survivors diagnosed at age ≤50 years may be at increased risk of 
hypertension. This study suggests that early post-diagnostic monitoring of CVD risk factors may 
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be warranted even in younger breast cancer survivors to reduce long-term CVD risk. Future 
longitudinal studies are needed to confirm these results.  
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High cholesterol  
(N=675) 




Cancer-free Survivorsa Cancer-free Survivorsa Cancer-free Survivorsa Cancer-free Survivorsa 
(n= 561) (n=216) (n=488) (n=187) (n=597) (n=231) (n=661) (n=261) 
Age, mean years (SD) 45.0(11.2)* 49.0(10.5)* 44.7(11.4)* 48.5(10.5)* 45.8(11.9)* 49.7(10.8)*  46.7(11.9)* 50.5(11.0)* 
White, % 91.7* 83.3* 90.0* 79.8* 89.7* 81.6* 90.7* 82.7* 
Education, ≥4-year college, %  79.8 82.9 78.9 82.8 76.8 80.7 78.4 80.8 
Postmenopausal, % 32.7* 49.0* 30.7* 46.8* 35.7* 50.6* 38.2* 53.0* 
Age at menopauseb, mean years 
(SD) 
48.9(6.8) 49.7(4.7) 49.3(5.3) 50.1(4.5) 49.0(6.6) 50.1(4.2) 49.0(6.6) 50.0(4.7) 
Bilateral oophorectomy at age  
<45 yearsc, % 
44.5 31.2 43.0 28.9 45.9* 21.3* 45.5* 24.9* 
BMI, mean kg/m2 (SD) 25.2(5.2) 24.9(5.3) 25.2(5.6) 25.2(5.8) 25.5(5.7) 25.1(5.7) 25.8(5.7) 25.3(5.4) 
Physical activity, mean MET-
h/weekd (SD)  
30.6(31.6) 27.5(31.3) 31.0(33.0) 26.7(32.2) 29.7(31.9) 27.3(32.2) 29.0(30.8) 26.8(30.8) 
Alcohol intake, mean g/day 
(SD) 
6.0(8.9) 5.6(8.7) 5.8(8.1) 6.4(9.9) 5.8(8.3) 6.0(9.6) 6.1(9.1) 5.9(9.5) 
Smoking status, %                 
  Never 59.6 57.4 63.0 60.1 60.8 57.4 59.2 55.2 
  Former 35.9 39.7 33.6 37.8 35.1 40.5 36.8 42.0 
  Current 4.2 2.5 3.2 1.7 3.8 1.7 3.7 2.5 
  Missing 0.2 0.4 0.2 0.5 0.4 0.4 0.3 0.3 
Hormone replacement therapy 
ever use, % 
18.2 15.2 17.1 16.2 18.6 17.7 20.8 18.6 
Ever mammograme, % 98.4 98.0 98.1 97.6 98.6 98.2 98.8 98.5 
Ever pap smear, % 98.4 98.9 99.0 98.7 98.8 98.9 98.7 98.8 
High cholesterol, % 23.1 23.0  -- --  20.4 19.4 28.5 27.9 
High blood pressure, % -- --  10.9 12.3 15.7 14.8 17.9 17.4 
High triglycerides, % 10.0 9.4 2.0 2.5 --   -- 13.2 10.3 
Diabetes, % 2.5 2.5 2.3 2.2 3.5 1.2  -- --  
Age at diagnosis, mean years 
(SD) 
-- 47.5(10.4) -- 47.1(10.4) -- 48.3(10.7) --  49.1(10.9) 
Time from diagnosis to 
baseline, mean years (SD) 
-- 1.4(1.3) -- 1.4(1.3) -- 1.4(1.3) --  1.4 (1.3) 
Breast cancer stage, %         
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  Stage 0 --  17.1 --  16.0 -- 17.8 --  17.6 
  Stage I-III --  81.0 --  83.4 --  81.0 --  80.8 
  Stage IV --  1.9 --  <1 --  1.3 --  1.5 
Estrogen receptor statusf, % --   --   --   --   
  Positive -- 76.5 -- 78.3 -- 77.9 --  78.6 
  Negative -- 22.9 -- 21.7 -- 21.6 --  20.9 
  Missing/untested -- <1 -- 0 -- <1 --  <1 
Breast cancer treatmentg, % --   --   --   --   
  Surgeryh -- 100.0 -- 100.0 -- 100.0 -- 100.0 
  Chemotherapy -- 49.5 -- 53.5 -- 50.7 --  49.0 
  Hormonal therapy, any -- 64.8 -- 65.2 -- 66.2 --  66.3 
  Hormonal therapy, by type --   --   --   --   
    Tamoxifen -- 70.0 -- 67.2 -- 66.0 --  63.6 
    Aromatase inhibitor -- 39.3 -- 40.2 -- 42.5 --  44.5 
Values are means(SD) or percentages and are age-adjusted 
* p<0.05 
a Women were diagnosed with stage 0-IV breast cancer ≤5 years prior to baseline 
b Among post-menopausal women 
c Among women who had both ovaries removed (n=72) 
d Metabolic equivalents from recreational and occupational activity 
e Among women aged ≥50 years 
f Among invasive cases only (n=179 for hypertension; n=157 for high cholesterol; n=192 for high triglycerides; n=215 for diabetes) 
g Treatment groups are not mutually exclusive and treatment with chemotherapy and hormonal therapy is adjuvant 
h Excluding women with stage IV breast cancer 
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Table 3-2. Hazard ratios and 95% confidence intervals for incident cardiovascular disease risk factors among breast cancer survivors compared to 
cancer-free women (continued on next page) 
  
  

















HR (95% CI) 
MV-adjusted 
HRa (95% CI) 
MV-adjusted 
HR + CVD 
risk factorsb 
(95% CI) 
Overall                 
  Cancer-free 45/3696 1.00 (ref) 1.00 (ref) 1.00 (ref) 50/3177 1.00 (ref) 1.00 (ref) 1.00 (ref) 












Sensitivity analyses                 
Excluding stage 0 breast cancer                 
  Cancer-free 45/3696 1.00 (ref) 1.00 (ref) 1.00 (ref) 50/3177 1.00 (ref) 1.00 (ref) 1.00 (ref) 












Excluding stage IV breast cancer                 
  Cancer-free 45/3696 1.00 (ref) 1.00 (ref) 1.00 (ref) 50/3177 1.00 (ref) 1.00 (ref) 1.00 (ref) 












Excluding early bilateral 
oophorectomy 
                
  Cancer-free 42/3540 1.00 (ref) 1.00 (ref) 1.00 (ref) 46/3089 1.00 (ref) 1.00 (ref) 1.00 (ref) 












Excluding pre- to post-menopausal                 
  Cancer-free 35/2477 1.00 (ref) 1.00 (ref) 1.00 (ref) 33/2147 1.00 (ref) 1.00 (ref) 1.00 (ref) 












Abbreviations: CVD, cardiovascular disease; MV, multivariable 
aModel adjusted for age (years), race (white, other), education status ( ≥4-year college, <4-year college), menopausal status at baseline (premenopausal, postmenopausal), body 
mass index (kg/m2), physical activity (MET-h/week), smoking status (never, ever), alcohol intake (grams/day) and hormone replacement therapy (never, ever) 
bModel mutually adjusted for other CVD risk factors: hypertension, high cholesterol, high triglycerides, and diabetes  
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HR (95% CI) 
MV-adjusted 
HRa (95% CI) 
MV-adjusted 
HR + CVD 






HR (95% CI) 
MV-adjusted 
HRa (95% CI) 
MV-adjusted 
HR + CVD 
risk factorsb  
(95% CI) 
Overall                 
  Cancer-free 12/4071 1.00 (ref) 1.00 (ref) 1.00 (ref) 21/4494 1.00 (ref) 1.00 (ref) 1.00 (ref) 












Sensitivity analyses                 
Excluding stage 0 breast cancer                 
  Cancer-free 12/4071 1.00 (ref) 1.00 (ref) 1.00 (ref) 21/4494 1.00 (ref) 1.00 (ref) 1.00 (ref) 












Excluding stage IV breast cancer                 
  Cancer-free 12/4071 1.00 (ref) 1.00 (ref) 1.00 (ref) 21/4494 1.00 (ref) 1.00 (ref) 1.00 (ref) 












Excluding early bilateral 
oophorectomyc 
                
  Cancer-free 8/3888 1.00 (ref) 1.00 (ref) 1.00 (ref) 21/4242 1.00 (ref) 1.00 (ref) 1.00 (ref) 












Excluding pre- to post-menopausal                 
  Cancer-free 11/2815 1.00 (ref) 1.00 (ref) 1.00 (ref) 12/3091 1.00 (ref) 1.00 (ref) 1.00 (ref) 












Abbreviations: CVD, cardiovascular disease; MV, multivariable 
a Model adjusted for age (years), race (white, other), education status ( ≥4-year college, <4-year college), menopausal status at baseline (premenopausal, postmenopausal), body 
mass index (kg/m2), physical activity (MET-h/week), smoking status (never, ever), alcohol intake (grams/day) and hormone replacement therapy (never, ever) 
bModel mutually adjusted for other CVD risk factors: hypertension, high cholesterol, high triglycerides, and diabetes  
c Model for incident high triglycerides that mutually adjusted for other CVD risk factors does not adjust for diabetes due to no women with prevalent diabetes 
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Table 3-3. Hazard ratios and 95% confidence intervals for incident cardiovascular disease risk factors in breast cancer survivors stratified by 
breast cancer characteristics compared to cancer-free women 
  Hypertension (N=777) High cholesterol (N=675) High triglycerides (N=828) 












Age at diagnosis             
  Cancer-free 45/3696 1.00 (ref) 50/3177 1.00 (ref) 12/4071 1.00 (ref) 
  ≤50 years 13/756 2.04 (1.04-4.00) 9/690 0.87 (0.41-1.83) 9/799 4.37 (1.66-11.53) 
  >50 years 7/509 0.76 (0.33-1.77) 12/387 1.19 (0.59-2.37) 9/588 3.58 (1.34-9.56) 
Menopausal status at diagnosis             
  Cancer-free 45/3696 1.00 (ref) 50/3177 1.00 (ref) 12/4071 1.00 (ref) 
  Premenopausal at diagnosis 15/852 1.72 (0.92-3.20) 11/759 0.79 (0.40-1.55) 10/892 3.51 (1.42-8.71) 
  Postmenopausal at diagnosis 5/413 0.70 (0.26-1.88) 10/319 1.30 (0.60-2.81) 8/495 3.20 (1.12-9.17) 
ER-statusb             
  Cancer-free 45/3696 1.00 (ref) 50/3177 1.00 (ref) 12/4071 1.00 (ref) 
  ER-negative 0/232 -- 4/178 1.45 (0.50-4.22) 6/214 7.61 (2.50-23.17) 
  ER-positive 15/778 1.52 (0.83-2.80) 14/692 0.98 (0.53-1.81) 10/893 3.29 (1.34-8.07) 
Abbreviations: CVD, cardiovascular disease; ER, estrogen-receptor; MV, multivariable 
a Adjusted for age (years), race (white, other), education status ( ≥4-year college, <4-year college), menopausal status at baseline (premenopausal, postmenopausal), body mass 
index (kg/m2), physical activity (MET-h/week), smoking status (never, ever), alcohol intake (grams/day) and hormone replacement therapy (never, ever) 







Table 3-4. Hazard ratios and 95% confidence intervals for incident cardiovascular disease risk factors among breast cancer survivors compared to 
cancer-free women stratified by baseline body mass index categories 
BMI categories 






















BMI <25 kg/m2                   
    Cancer-free 12/2187 1.00 (ref) 
0.64 
23/1910 1.00 (ref) 
0.71 
7/2232 1.00 (ref) 
0.10 
    Survivors 5/804 0.91 (0.30-2.75) 9/667 0.80 (0.36-1.81) 7/849 2.20 (0.69-7.04) 
BMI ≥25 kg/m2             
    Cancer-free 33/1510 1.00 (ref) 27/1266 1.00 (ref) 5/1838 1.00 (ref) 
    Survivors 15/461 1.54 (0.81-2.92) 12/411 1.18 (0.58-2.39) 11/538 7.88 (2.61-23.79) 
Abbreviations: HR, hazard ratios; CI, confidence interval; MV, multivariable; BMI, body mass index 
aModel adjusted for age (years), race (white, other), education status ( ≥4-year college, <4-year college), menopausal status at baseline (premenopausal, postmenopausal), 
body mass index (kg/m2), physical activity (MET-h/week), smoking status (never, ever), alcohol intake (grams/day) and hormone replacement therapy (never, ever) 
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Chapter 4.  
 
Evaluation of osteopenia and osteoporosis in younger breast cancer survivors compared 












Background: Osteoporosis has been consistently reported among older breast cancer survivors. 
However, data is limited on the incidence of osteoporosis and osteopenia, an earlier indicator of 
bone loss, in breast cancer survivors relative to their cancer-free peers. 
 
Methods: We identified 211 survivors diagnosed with breast cancer ≤5 years prior to baseline 
and 567 cancer-free women from an ongoing familial risk cohort. Multivariable (MV)-adjusted 
Cox proportional hazard models were used to estimate hazard ratios (HRs) and 95% confidence 
intervals (CIs) of incident osteopenia and/or osteoporosis based on physician diagnosis. 
 
Results: Mean age at diagnosis was 47 years. During a mean follow-up time of 5.8 years, 66% of 
breast cancer survivors and 53% of cancer-free women reported having a bone density exam and 
112 incident cases of osteopenia/osteoporosis were identified. Overall, breast cancer survivors 
had a 68% higher risk of osteopenia and osteoporosis compared to cancer-free women (MV-
HR=1.68, 95% CI=1.12-2.50). The association was stronger among recent survivors after only 2 
years of follow-up (MV-HR=2.74, 95% CI=1.37-5.47). A higher risk of osteopenia and 
osteoporosis was also observed among the following subgroups; survivors ≤50 years, survivors 
with ER positive tumors, and survivors treated with aromatase inhibitors (AI) alone or with 
chemotherapy plus any hormonal therapy when compared to cancer-free women.  
 
Conclusion Young breast cancer survivors are at higher risk for osteopenia and osteoporosis 
compared to cancer-free individuals. Studies are needed to determine effective approaches to 






Osteopenia and osteoporosis, both systemic skeletal conditions associated with varying degrees of 
bone loss, are prevalent among postmenopausal breast cancer survivors with reports of up to 80% 
of survivors experiencing bone loss.1 Osteopenia is diagnosed among individuals with lower than 
average bone density while osteoporosis is characterized by even lower bone density and 
architectural deterioration of bone tissue.2 Untreated bone loss can also lead to subsequent 
fractures and death.3 Among breast cancer survivors, cancer-related risk factors for osteopenia 
and osteoporosis include both treatment and premature menopause.1,4 The excess risk of 
osteopenia and osteoporosis among breast cancer survivors relative to their cancer-free peers 
remains unknown. 
 
Osteopenia and osteoporosis are also common conditions in the general population. Among 
women aged ≥50 years in the United States, approximately 15.4% have osteoporosis and 51.4% 
have low bone density.5 Furthermore, 1 in 2 women will be at risk for an osteoporosis-related 
fracture during their lifetime.6 Among cancer-free women, loss in bone density is due to 
advancing age, menopause induced estrogen deficiency, and other modifiable factors including 
low body weight, lack of physical activity, excess alcohol consumption, family history of bone 
fracture, cigarette smoking, low calcium intake, and vitamin D deficiency.4,7 Loss of bone density 
in breast cancer survivors could be due to similar risk factors in addition to treatment related 
effects. By comparing cancer survivors to cancer-free individuals, we are able to differentiate 
between these risk factors. 
 
Few epidemiologic studies have examined osteopenia and osteoporosis in breast cancer survivors 




lower levels of bone mineral density,8 the gold standard for assessing bone loss, and two other 
previous studies observed an increased risk of osteopenia and osteoporosis9,10 compared to 
cancer-free women. These studies were primarily conducted among older and long-term breast 
cancer survivors and did not differentiate based on tumor subtypes and detailed treatment 
regimens. One reason for the paucity of studies among younger breast cancer survivors is likely 
the challenge of identifying a comparable cancer-free group as young cancer-free women do not 
routinely undergo assessment of their bone health. Fortunately, we found this not to be the case in 
women with familial breast cancer risk. In this study, we examined the risk of osteopenia and 
osteoporosis in young breast cancer survivors compared to cancer-free women in a familial risk 





The Breast and Ovarian Surveillance Service (BOSS) study is an ongoing prospective cohort 
study that enrolled women and men with familial risk for breast and/or ovarian cancer.11 
Participants were enrolled from 2005-2013 primarily from the cancer genetics clinic at the John 
Hopkins Sidney Kimmel Comprehensive Cancer Center in Baltimore, Maryland. Eligible 
participants were aged ≥18 years with either: 1) a family history of breast and/or ovarian cancer, 
2) a documented BRCA1/2 mutation, 3) a diagnosis with breast cancer at ≤40 years of age 
without a family history of breast cancer, or 4) a diagnosis with ovarian cancer at any age without 
a family history of ovarian cancer. Participants completed a baseline questionnaire to collect 
information on a variety of demographic, lifestyle, and health factors including detailed 




have been completed every 3-4 years thereafter (>92% have completed at least 1 follow-up 
questionnaire). Completion of the second follow-up questionnaire is ongoing. 
 
For the present analysis, women were included if they completed a baseline questionnaire and at 
least 1 follow-up questionnaire through September 30th, 2017 (n=1,173). Women with a 
physician diagnosis of osteopenia or osteoporosis at baseline (n=272 total; n=174 with osteopenia 
only; n=46 osteoporosis only) or bisphosphonate use at baseline (n=5) were excluded. We further 
excluded women with missing responses for osteopenia or osteoporosis on baseline (n=1) or 
follow-up questionnaires (n=5). For this analysis, breast cancer survivors were defined as women 
diagnosed with breast cancer (ductal carcinoma in situ [stage 0] or stage I-III breast cancer) 
within 5 years prior to enrollment. The comparison group was restricted to women with no prior 
history of cancer at baseline except non-melanoma skin cancer or cervical carcinoma in situ. 
After these exclusions, 778 women (211 breast cancer survivors and 567 cancer-free) became our 
analytic study population. 
 
Ascertainment of breast cancer and treatment 
 
Cancer diagnoses were self-reported at enrollment and pathology records were reviewed to 
confirm breast cancer diagnosis (International Classification of Disease-10 code: invasive breast 
cancer [C50]; ductal carcinoma in situ [D05.1] and lobular carcinoma in situ [D05.0]) as well as 
stage and hormonal receptor status (estrogen/progesterone receptor and HER2 status). Breast 
cancer treatment was reported in baseline questionnaires and details were confirmed with medical 
record review (96% confirmed). Treatment information included surgery (none, lumpectomy, 
mastectomy), and adjuvant therapy (chemotherapy, radiation, and hormonal therapy). Detailed 
information on type of chemotherapy and hormonal therapy was also collected. We classified 




chemotherapy alone, and chemotherapy plus hormonal therapy. Hormonal therapy was further 
classified as tamoxifen or aromatase inhibitor use.  
 
Ascertainment of osteopenia and osteoporosis  
 
Osteopenia and osteoporosis diagnoses were ascertained in baseline and follow-up 
questionnaires. In each questionnaire, participants were asked to indicate whether they had 
received a physician’s diagnosis and the year of diagnosis for osteopenia and osteoporosis. 
Incident cases of osteopenia and osteoporosis were identified on follow-up questionnaires. Our 
outcome of interest was a composite outcome that included incident osteopenia and/or 
osteoporosis. Participants also reported whether they ever had a bone density exam and the year 
of exam on both baseline and follow-up questionnaires. 
 
Ascertainment of covariates 
 
Information on covariates (age, race, education level, menopausal status, age at menopause, 
oophorectomy at a young age, body mass index [BMI], physical activity based on metabolic 
equivalents of task [METs] per week, alcohol intake, smoking status, hormonal replacement 
therapy [HRT] use, current bisphosphonate use, history of screening [mammography, pap smear], 
vitamin D supplement use, and calcium supplement use) were available from the baseline 
questionnaire. Bilateral oophorectomy at a young age was defined as both ovaries removed prior 
to age 45 years and based on self-report. We calculated age at bilateral oophorectomy from the 
date that the second ovary was removed. Year of medical procedures and screening exams, 
including mammograms, pap smears, sigmoidoscopy, and colonoscopy, were also reported on 







Baseline characteristics of breast cancer survivors and cancer-free women were compared with 
frequency distributions for categorical variables and means (SDs) for continuous variables. We 
used Cox proportional hazard models with age as the time scale to calculate hazard ratios (HRs) 
and 95% confidence intervals (CIs). Women contributed person-time from the completion date of 
the baseline questionnaire to the date of osteopenia or osteoporosis diagnosis or until end of last 
follow-up through September 30th, 2017, whichever occurred first. The proportional hazards 
assumption was assessed with log-log survival plots and Schoenfeld residuals; neither method 
indicated that the assumption of proportional hazards by breast cancer status was violated. 
Confounders were identified a priori as variables that may be associated with both breast cancer 
incidence and osteopenia/osteoporosis. Multivariable models were adjusted for menopausal status 
(premenopausal, postmenopausal), hormone replacement therapy (ever, never), body mass index 
(BMI) (kg/m2), bilateral oophorectomy at age <45 years (yes, no), physical activity (MET-
h/week), smoking status (ever, never) and alcohol use (g/day). To account for a small percent of 
missing (< 1% missing), we imputed missing data with the most common category for categorical 
covariates and the median value for continuous covariates among cancer-free women. Our 
primary models were conducted among women diagnosed with stage 0-III breast cancer relative 
to cancer-free women. In addition, we also conducted all analyses with breast cancer status 
restricted to invasive cancer (stage I-III) relative to cancer-free women.  
 
We conducted several sensitivity analyses. First, we restricted our analytic population to women 
who reported having a prior bone density exam at baseline to reduce the potential inclusion of 
undiagnosed prevalent cases. Second, we restricted our analytic population to women who 
reported a bone density exam during follow-up to reduce the potential misclassification of 




over follow-up to determine if menopause might drive the development of bone loss. Finally, we 
ran several models that excluded women who reported a bilateral oophorectomy at age <45 years, 
vitamin D use at baseline, or calcium use at baseline.  
 
We also examined the risk of osteopenia and osteoporosis in women with breast cancer stratified 
by age at diagnosis, menopausal status at diagnosis, estrogen-receptor (ER) tumor status, and 
breast cancer treatment relative to cancer-free women. For models that stratified breast cancer 
survivors by ER-status, survivors were restricted to invasive breast cancer since ER status was 
not routinely measured in women with a stage 0 diagnosis. We additionally conducted several 
exploratory analyses by family history of breast cancer (no family history, first degree relative 
only, first and second degree relative) and BRCA 1/2 carrier status among a subgroup of women 
with genetic testing. We were unable to conduct analyses by HER2 status or triple negative breast 
cancer due to small numbers. 
 
Finally, to examine whether risk of osteopenia and osteoporosis varied by time since diagnosis, 
we used time since enrollment as the time metric and restricted breast cancer survivors to women 
diagnosed within 1 year prior to enrollment. Models were then stratified by follow-up time (≤2 
years and >2 years) and heterogeneity was tested using the likelihood ratio test.  
 
Analyses were conducted using SAS version 9.4 (SAS Institute Inc., Cary, NC, USA) and Stata 
version 14.0 (Stata Corp LP, College Station, TX, USA). All statistical tests were two-side and P 







Table 4-1 describes age and age-adjusted baseline characteristics of 778 women by breast cancer 
status (211 breast cancer survivors and 567 cancer-free women). Compared to cancer-free 
women, breast cancer survivors were more likely to be slightly older, postmenopausal, and 
current vitamin D users and less likely to have a bilateral oophorectomy at a young age and a 
family history of breast cancer. Both groups were predominately white and highly educated (≥4-
years of college). Among breast cancer survivors, the mean time from diagnosis to enrollment 
was 1.4 years and the mean age at diagnosis was 47 years. Over 80% of breast cancer survivors 
were diagnosed with a first invasive breast cancer and 76% had ER-positive breast tumors. In 
addition, all breast cancer survivors received surgery prior to adjuvant therapy, 65% of breast 
cancer survivors received any hormonal therapy (67% tamoxifen, 41% aromatase inhibitors) and 
50% received any chemotherapy.  
 
During an average of 5.8 years of follow-up, there were 112 incident cases of osteopenia and/or 
osteoporosis (75% osteopenia only). The incidence rate for osteopenia and osteoporosis was 44 
cases/1000 person-years among breast cancer survivors compared to 19 cases/1,000 person-years 
in cancer-free women.  Overall, breast cancer survivors had a 68% higher risk of osteopenia and 
osteoporosis compared to cancer-free women (MV-HR=1.68, 95% CI=1.12-2.50) (Table 4-2). 
The magnitude of risk was even stronger among invasive breast cancer survivors compared to 
cancer-free women (MV-HR=1.90; 95% CI=1.24-2.90).  Our results were similar to our primary 
analysis when we restricted our analytic population to women who reported having a bone 
density exam prior to baseline and during follow-up (MV-HR=1.90, 95% CI=1.08-3.34; MV-
HR=1.72, 95% CI=1.14-2.58, respectively). Results were also similar when we excluded women 
who had premature menopause secondary to a bilateral oophorectomy at age <45 years (MV-
HR=1.63, 95% CI=1.08-2.46) and only slightly attenuated when we restricted our analysis to 
women with no change in menopause status during follow-up (MV-HR=1.57, 95% CI=0.93-




vitamin D use at baseline (MV-HR=1.68, 95% CI=1.08-2.61) and became slightly attenuated 
among women without calcium use at baseline (MV- HR= 1.59, 95% CI=0.95-2.68). 
 
Next, we examined the risk of osteopenia and osteoporosis in breast cancer survivors stratified by 
age at diagnosis, menopausal status at diagnosis, and ER-status compared to cancer-free women 
(Table 4-3). Breast cancer survivors diagnosed at age ≤50 years had an almost 2-fold increased 
risk of osteopenia and osteoporosis compared to cancer-free women (HR=1.98, 95% CI=1.21-
3.24). Surprisingly, the association was not significant in older women. In addition, breast cancer 
survivors who were premenopausal at diagnosis had increased risk of osteopenia and osteoporosis 
relative to their cancer-free peers (MV-HR=1.76, 95% CI=1.09-2.84) and this risk was similar, 
but attenuated, among women who were postmenopausal at diagnosis (MV-HR=1.58, 95% 
CI=0.86-2.89). Finally, women with ER-positive tumors had an over 2-fold increased risk of 
osteopenia and osteoporosis compared to cancer-free women (MV-HR=2.10; 95%=1.34-3.29). 
Although women with ER-negative tumors had a modest increased risk of osteopenia and 
osteoporosis relative to their cancer-free peers, the association was not statistically significant 
(MV-HR=1.26; 95% CI=0.54-2.94). In exploratory analyses, results were attenuated but did not 
differ by family history of breast cancer and BRCA 1/2 carrier status (data not shown). 
 
We then evaluated risk of osteopenia and osteoporosis in breast cancer survivors stratified by 
breast cancer treatment compared to cancer-free women (Figure 4-1). Breast cancer survivors 
treated with chemotherapy plus hormonal therapy had over 2-fold increased risk of incident 
osteopenia and osteoporosis compared to cancer-free women (MV-HR=2.70; 95% CI=1.56-4.68). 
No significant association was observed for breast cancer survivors treated with surgery, 
chemotherapy, or hormonal therapy alone compared to cancer-free women. Breast cancer 
survivors treated with aromatase inhibitors alone and combined chemotherapy plus aromatase 




cancer-free women (MV-HR=2.72, 95% CI=1.31-5.65; MV-HR=3.83, 95% CI=1.87-7.83, 
respectively). In addition, breast cancer survivors treated with chemotherapy plus tamoxifen had 
an over 2-fold increased risk compared to cancer-free women (MV-HR=2.48, 95% CI=1.16-
5.30).  
 
Finally, breast cancer survivors diagnosed within 1 year prior to enrollment had an over 2-fold 
increased risk of osteopenia and osteoporosis compared to their cancer-free peers within the first 
2 years of follow-up (MV-HR=2.74, 95% CI=1.37-5.47) and a non-significant 85% increased risk 
of osteopenia and osteoporosis after 2-years of follow-up (MV-HR=1.85, 95% CI=0.98-3.51), 




To our knowledge this is the first study to prospectively assess risk of osteopenia and 
osteoporosis in young and recently diagnosed breast cancer survivors compared to their cancer-
free peers in a familial high risk cohort. In this study, the risk of osteopenia and osteoporosis was 
almost two-fold higher in breast cancer survivors compared to cancer-free women over an 
average of 5.8 years of follow-up. Breast cancer survivors who were aged 50 years or younger at 
diagnosis, had ER+ tumors, received AIs alone, or combined chemotherapy with AI or tamoxifen 
hormone therapy had a higher risk of osteopenia and osteoporosis compared to cancer-free 
women. This is after accounting for age, menopause and other risk factors for bone loss. 
 
The majority of studies have used a case-only design to examine bone health in breast cancer 
survivors.12-20 Several studies have found a higher risk of fracture in women diagnosed with 




Even fewer epidemiologic studies have assessed osteopenia and osteoporosis risk in women with 
breast cancer compared to their cancer-free peers within the same cohort.8-10 Furthermore, these 
studies have included primarily older and long-term survivors. The first of these studies was 
conducted among the Women’s Health Initiative Observational Study (WHI-OS). This study 
compared the prevalence of osteoporosis and the rate of bone loss in post-menopausal breast 
cancer survivors compared to cancer-free women.8 Although the investigators found that breast 
cancer survivors had a higher prevalence of low bone density and osteoporosis at baseline, they 
did not have an increased rate of bone loss compared to cancer-free women over follow-up.  A 
limitation of this study was that breast cancer survivors were identified from prevalent cases at 
study enrollment and the time from breast cancer diagnosis to study enrollment was not reported. 
It is possible that the rate of bone loss may have been assessed too distal to cancer diagnosis or 
treatment cessation, particularly if substantial bone loss occurs shortly after diagnosis or 
treatment.  
 
The second study was a retrospective registry study in the Cancer Genetics Network (CGN) 
conducted to assess early and late effects of cancer treatment.9 In this study, the authors assessed 
osteopenia and osteoporosis risk based on self-report in women with and without invasive breast 
cancer and found a significant positive association for both outcomes (HR: 2.1, 95% CI: 1.8-2.4 
for osteopenia; HR: 1.5, 95% CI: 1.2-1.9 for osteoporosis). Although this study included younger 
women with familial cancer risk, breast cancer survivors were identified from 1990 to 2009 and 
history of bone health was collected retrospectively in 2009. Among these breast cancer 
survivors, over 70% were diagnosed ≥10 years prior to the assessment of self-reported bone 
health in 2009 and thus susceptible to substantial recall bias.  
 
The third study was conducted among the UK general practice research database (GPRD) to 




(overall mean age [SD]=66.9 years [12.3 years]).10 The authors assessed osteoporosis risk, but not 
osteopenia, based on medical records among breast cancer survivors and found that survivors had 
a 26% higher risk of osteoporosis compared to cancer-free women (HR: 1.26, 95% CI: 1.13-
1.40).  No prior study has assessed bone loss by tumor subtype or incorporated detailed 
information on cancer treatment and bone scan history. In addition, only one previous study 
assessed osteopenia risk,9 an earlier indication of bone loss, which is also associated with a high 
fracture risk. 
 
The most common cause of bone loss in women is menopause and aging. Aging is associated 
with greater bone resorption and less bone formation while menopause induces accelerated bone 
loss due to lowering levels of endogenous estrogen.26 Therefore, a cancer-free comparison of 
similar age and menopausal status is important when assessing bone loss. Given that we still 
observed significantly higher bone loss in breast cancer survivors relative to their cancer-free 
peers after accounting for age and and menopause, it is likely that additional bone loss is due to 
the effect of treatment on bone formation.  
 
We observed the highest risk of osteopenia and osteoporosis among breast cancer survivors 
treated with AIs alone and chemotherapy plus AIs. These findings are in agreement with the 
underlying biology of AIs27 as well as case only studies in survivors 16-20 and high-risk women in 
chemoprevention trials.28,29 AIs, prescribed to post-menopausal women with ER-positive tumors, 
block the aromatase enzyme resulting in a hypoestrogen state which is associated with bone 
loss.27 We found no association among women with tamoxifen use alone, a group that was 
primarily premenopausal at baseline (mean age at baseline=46 years; 76% premenopausal at 
baseline). However, we did observe an almost 2-fold increased risk of osteopenia and 
osteoporosis among women with chemotherapy plus tamoxifen use (mean age at baseline=43; 




generally thought to be protective against bone loss in postmenopausal women,30 reports suggest 
that it may cause bone loss among premenopausal women.13,31 It is hypothesized that 
chemotherapy may also cause bone loss due to treament induced premature menopause in 
premenopausal women32 and may also have direct toxic effects on bone formation cells.27 In 
addition, medications commonly presribed along with chemotherapy (e.g., steroids) have also 
been associated with bone loss.33 Therefore, it is biologically plausible that chemotherapy plus 
hormonal therapy, including tamoxifen, might have a joint deleterious effect on bone health.  
 
The strengths of this study include the prospective study design, direct comparison to cancer-free 
women from the same cohort, and detailed information on cancer treatment. There are also 
several limitations to our prospective analysis. First, our sample size may have limited our power 
to detect small to moderate associations. Second, osteopenia and osteporosis incidence was 
ascertained based on self-reported physican diagnosis and may be susceptible to misclassification. 
However 96% of women who reported a diagnosis of osteopenia or osteopororisis also reported 
receiving a bone scan and analyses restricted to women who reported having a bone scan during 
follow-up were similar. Third, breast cancer survivors may have had increased surveillance for 
bone health and therefore, screening might not have been comparable to cancer-free women. It is 
possible that osteopenia or osteoporosis may be underdiagnosed in cancer-free women. However, 
overall health screening history was similar at baseline among breast cancer survivors vs. cancer-
free women (e.g., 99.1% of breast cancer survivors vs 98.8% cancer-free women ever had a pap-
smear; 97.8% of breast cancer survivors vs. 99.5% of cancer-free women ever had a mammogram 
among women aged ≥ 50 years). In addition, compared to cancer-free women, breast cancer 
survivors were only slightly more likely to have had a bone density exam at baseline (43% vs. 
29%; 60% vs. 51% among women aged ≥45 years) and follow-up (66% vs 53%). To further 
reduce the possibility of undetected prevalent cases, we restricted our analysis to women with 




Finally, our results may not be generalizable to other populations since our study population was 
predominately white and highly educated women at high risk for breast cancer. However, we 
believe that the underlying biology is likely similar across ethnicities. Future studies in more 
diverse populations are needed. The homogeniety of our study population however improves the 
internal validity of this study as it reduces the influence of potential unmeasured factors.  
 
In summary, our results demonstrate that incident osteoporosis and osteopenia is significantly 
higher in young breast cancer survivors with familial risk compared to cancer-free women and 
risk varies by cancer subtype and breast cancer treatment. These findings provide support for a 
baseline evaluation of bone density and fracture risk assessment close to breast cancer diagnosis, 
particularly among young breast cancer survivors being treated with combined chemotherapy and 
hormone therapy, so that prevention strategies and appropriate monitoring can be implemented. 
Future studies are needed to address the frequency of monitoring in breast cancer survivors by 




Table 4-1. Age- and age-adjusted baseline characteristics of cancer-free women and breast cancer 
survivors in the BOSS cohort study 
Characteristic 
Cancer-free  Survivorsa  p-value 
(n=567) (n=211) 
Age b, mean years (SD) 44.7 (11.3) 48.1 (10.3) <0.001 
White, % 88.7 83.3 0.02 
Education, ≥4-year college, %  77.6 77.4 0.72 
Postmenopausal, % 27.4 51.6 <0.001 
Age at menopausec, mean years (SD) 49.6 (4.9) 48.8 (3.4) 0.86 
Bilateral oophorectomy at age < 45 yearsd, % 49.0 34.3 0.02 
BMI, mean kg/m2 (SD) 26.2 (5.1) 25.9 (3.1) 0.29 
Physical activity, mean MET-h/weeke (SD)  29.4 (27.9) 26.0 (15.5) 0.29 
Alcohol intake, mean g/day (SD) 5.7 (7.5) 5.7 (4.8) 0.99 
Smoking status, %       
  Never 58.8 52.5 0.55 
  Former 36.7 44.8 
  Current 4.2 2.7 
  Missing 0.3 0.0   
Hormone replacement therapy ever use, % 15.1 14.5 0.04 
Ever mammogramf, % 99.5 97.8 0.63 
Ever pap smear, % 98.6 99.1 0.15 
Current vitamin D supplement use, % 7.8 20.8 <0.001 
Current calcium supplement use, % 25.5 28.1 0.97 
Bone density screening, % 28.9 43.0 0.02 
Bone density screening in women aged ≥45 years, % 51.2 60.0 0.08 
Ever broken bone, % 6.4 6.8 0.84 
Family history of breast cancer, %    
  No family history of breast cancer 14.7 38.9 <0.001 
  First degree relative only 64.8 50.7 
  First and second degree relative  17.0 9.0 
  Missing 3.5 1.4 
BRCA 1/2 statusg, %    
  Negative  69.7 73.9 0.33 
  Positive 27.3 19.4 
  Variants of uncertain significance 2.9 6.7 
Age at diagnosis, mean years (SD) -- 46.8 (10.2) -- 
Time from diagnosis to baseline, mean years (SD) -- 1.4 (1.3) -- 
Invasive breast cancer (stage I-III), % -- 82.5 -- 
Estrogen receptor statush, % --   -- 
  Positive -- 75.9 -- 
  Negative -- 23.6 -- 
  Missing/untested -- <1 -- 
HER2 statush, % --  -- 
  Positive -- 14.4 -- 




  Missing/untested -- 3.5 -- 
Triple negative statush, % -- 19.0 -- 
Breast cancer treatmenti,j, % --   -- 
  Surgery -- 100.0 -- 
  Chemotherapy -- 49.8 -- 
  Hormonal therapy, any -- 65.4 -- 
  Hormonal therapy k, by type  --   -- 
    Tamoxifen -- 67.4 -- 
    Aromatase inhibitor -- 41.3 -- 
Abbreviations: HER2, human epidermal  growth factor receptor 2  
Values are means(SD) or percentages and are standardized to the age distribution of the study population 
a Women were diagnosed with stage 0-III breast cancer ≤5 years prior to baseline 
b Value is not age-adjusted 
c Among post-menopausal women 
d Among women who had both ovaries removed (n=86) 
e Metabolic equivalents from recreational and occupational activity  
f Among women aged ≥50 years 
g Among women tested for BRCA status (n=414) 
h Among invasive cases only (n=174) 
i Treatment groups are not mutually exclusive 
j Chemotherapy and hormonal therapy are adjuvant  




Table 4-2. Hazard ratios and 95% confidence intervals for incident osteopenia and osteoporosis among breast cancer survivors compared to 
cancer-free women 
   






HR (95% CI) 
MV-adjusted 





HR (95% CI) 
MV-adjusted 
HRa (95% CI) 
Overall             
   Cancer-free 67/3509 1.00 (ref) 1.00 (ref) 67/3509 1.00 (ref) 1.00 (ref) 
   Breast cancer survivors 45/1026 2.01 (1.38-2.94) 1.68 (1.12-2.50) 39/819 2.18 (1.46-3.24) 1.90 (1.24-2.90) 
Excluding women without bone density exams prior to 
baseline 
            
    Cancer-free 27/1023 1.00 (ref) 1.00 (ref) 27/1023 1.00 (ref) 1.00 (ref) 
    Breast cancer survivors 27/497 1.96 (1.15-3.36) 1.90 (1.08-3.34) 23/400 2.10 (1.20-3.67) 2.13 (1.17-3.90) 





      
    Cancer-free 63/1890 1.00 (ref) 1.00 (ref) 63/1890 1.00 (ref) 1.00 (ref) 
    Breast cancer survivors 45/703 1.89 (1.29-2.78) 1.72 (1.14-2.58) 39/577 1.98 (1.33-2.97) 1.91 (1.24-2.93) 
Excluding early bilateral oophorectomy prior to baselineb             
    Cancer-free 64/3347 1.00 (ref) 1.00 (ref) 64/3347 1.00 (ref) 1.00 (ref) 
    Breast cancer survivors 42/957 1.93 (1.30-2.85) 1.63 (1.08-2.46) 36/755 2.08 (1.38-3.14) 1.85 (1.19-2.86) 
Excluding pre- to post-menopausal during follow-up             
    Cancer-free 34/2308 1.00 (ref) 1.00 (ref) 34/2308 1.00 (ref) 1.00 (ref) 
    Breast cancer survivors 32/745 2.18 (1.34-3.55) 1.57 (0.93-2.63) 28/595 2.38 (1.44-3.95) 1.71 (0.99-2.94) 
Excluding current vitamin D usersc             
    Cancer-free 60/3263 1.00 (ref) 1.00 (ref) 60/3263 1.00 (ref) 1.00 (ref) 
    Breast cancer survivors 36/820 2.03 (1.34-3.08) 1.68 (1.08-2.61) 31/661 2.20 (1.42-3.40) 1.93 (1.21-3.09) 
Excluding current calcium usersc             
    Cancer-free 40/2637 1.00 (ref) 1.00 (ref) 40/2637 1.00 (ref) 1.00 (ref) 
    Breast cancer survivors 28/743 2.14 (1.32-3.48) 1.59 (0.95-2.68) 24/625 2.24 (1.35-3.74) 1.78 (1.03-3.08) 
Abbreviations: HR, hazard ratios; CI, confidence interval; MV, multivariable  
aAdjusted for age (years), menopausal status (premenopausal, postmenopausal), bilateral oophorectomy at age <45 years (yes, no), body mass index (kg/m2), physical activity 
(MET-h/week), smoking status (never, ever), alcohol intake (grams/day) and hormone replacement therapy (never, ever) 
b Both ovaries removed prior to age 45 years 






Table 4-3. Hazard ratios and 95% confidence intervals for incident osteopenia and osteoporosis among breast cancer survivors stratified by breast 
cancer characteristics compared to cancer-free women 

















Age at diagnosis               
  Cancer-free 67/3509 1.00 (ref) 1.00 (ref)   67/3509 1.00 (ref) 1.00 (ref) 
  ≤50 years 27/651 2.34 (1.46-3.75) 1.98 (1.21-3.24)   24/510 2.67 (1.63-4.36) 2.34 (1.39-3.95) 
  >50 years 18/375 1.64 (0.93-2.88) 1.34 (0.75-2.40)   15/309 1.64 (0.90-2.99) 1.45 (0.78-2.67) 
Menopause status at diagnosis               
  Cancer-free 67/3509 1.00 (ref) 1.00 (ref)   67/3509 1.00 (ref) 1.00 (ref) 
  Premenopausal at diagnosis 27/728 1.97 (1.24-3.12) 1.76 (1.09-2.84)   24/579 2.22 (1.37-3.59) 2.11 (1.27-3.52) 
  Postmenopausal at diagnosis 18/298 2.05 (1.15-3.64) 1.58 (0.86-2.89)   15/240 2.13 (1.15-3.92) 1.70 (0.90-3.23) 
ER-status               
  Cancer-free -- -- --   67/3509 1.00 (ref) 1.00 (ref) 
  ER-negative -- -- --   7/200 1.68 (0.76-3.72) 1.26 (0.54-2.94) 
  ER-positive -- -- --   32/611 2.32 (1.52-3.55) 2.10 (1.34-3.29) 
Abbreviations: HR, hazard ratios; CI, confidence interval; MV, multivariable; ER, estrogen-receptor 
aAdjusted for age (years), menopausal status (premenopausal, postmenopausal), bilateral oophorectomy at age <45 years (yes, no), body mass index (kg/m2), physical activity 








Table 4-4. Hazard ratios and 95% confidence intervals for incident osteopenia and osteoporosis among recent breast cancer survivors compared to 
cancer-free women stratified by follow-up time 






HR (95% CI) 
pb 
MV-adjusted 






HR (95% CI) 
pb 
MV-adjusted 
HRc (95% CI) 
pb 
Overall                     








   Breast cancer survivors 27/475 2.49 (1.58-3.91) 2.17 (1.37-3.46) 22/385 2.47 (1.51-4.03) 2.18 (1.32-3.59) 
0-2 years                     








   Breast cancer survivors 14/214 3.15 (1.61-6.17) 2.74 (1.37-5.47) 12/182 3.17 (1.56-6.41) 2.76 (1.34-5.70) 
3+ years             
   Cancer-free 45/2371 1.00 (ref) 1.00 (ref) 45/2371 1.00 (ref) 1.00 (ref) 
   Breast cancer survivors 13/261 2.07 (1.11-3.85) 1.85 (0.98-3.51) 10/203 1.99 (1.00-3.99) 1.80 (0.89-3.66) 
Abbreviations: HR, hazard ratios; CI, confidence interval; MV, multivariable 
a Breast cancer survivors were restricted to women diagnosed within 1 year prior to enrollment 
b P value for likelihood ratio test of interaction between breast cancer status and time 
c Adjusted for age (years), menopausal status (premenopausal, postmenopausal), bilateral oophorectomy at age <45 years (yes, no), body mass index (kg/m2), physical activity 





Figure 4-1. Multivariable-adjusted hazard ratios and 95% confidence intervals for incident 
osteopenia and osteoporosis among breast cancer survivors stratified by type of treatment 
compared to cancer-free women 
Abbreviations: BC, breast cancer; PT, person time in years; HR, hazard ratio; CI, confidence interval; HT, hormone 
therapy; AI, aromatase inhibitor 
 
Models are adjusted for age (years), menopausal status (premenopausal, postmenopausal), bilateral oophorectomy at 
age <45 years (yes, no), body mass index (kg/m2), physical activity (MET-h/week), smoking status (never, ever), 
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Summary of findings 
 
There is an increasing population of over 3.5 million breast cancer survivors in the United States 
and many of these women will become long-term survivors with 5-year survival rates now 
exceeding 90%.1,2 The overarching goal of this dissertation was to examine the impact of breast 
cancer and treatment on several adverse outcomes by utilizing a cancer-free comparison from the 
same cohort and controlling for the effects of aging, menopause, and lifestyle factors. Although 
bone loss and cardiovascular disease have been reported in breast cancer survivors, the excess 
risk of these outcomes relative to cancer-free women remains unclear. This dissertation examined 
the association between bone loss, CVD risk factors, and all-cause and CVD-related mortality in 
breast cancer survivors compared to cancer-free women. Determining whether breast cancer 
survivors have a higher risk of these adverse outcomes compared to cancer-free women helps 
inform the need for tailored treatment and prevention strategies to continue to improve the long-
term prognosis after breast cancer. 
 
Chapter 2: All-cause and CVD-related mortality in women with breast cancer  
 
In chapter 2, we examined the risk of all-cause and CVD-related mortality in breast cancer 
survivors compared to cancer free women in CLUE II, a community-based cohort with over 20-
years of follow-up. We further examined this association by breast cancer prognostic factors and 
time since diagnosis. Overall, we observed a 79% higher risk of all-cause mortality in breast 
cancer survivors compared to cancer-free women and this increased risk remained 15 years after 




need to further identify ways to reduce the risk of long-term all-cause mortality among breast 
cancer survivors. 
 
We also found that risk of all-cause mortality was higher regardless of age at diagnosis. However, 
risk of all-cause mortality remained steady over time among women diagnosed at age <70 years 
while this risk increased over time among women diagnosed at age ≥70 years. After 15 years, risk 
of all-cause mortality was almost 3-fold higher among women diagnosed at age ≥70 years 
compared to women of similar age without breast cancer. These findings suggest that the risk of 
dying from any cause differs over time by age at diagnosis, and therefore supports more 
personalized interventions, particularly among older survivors, to carefully balance the risks and 
benefits of treatment. 
 
We also observed that breast cancer survivors may have a higher risk of CVD-mortality 
compared to cancer-free women, and this increased risk begins to manifest several years after 
diagnosis, particularly among women diagnosed at age ≥70 years and women with ER-positive 
tumors. These findings suggest a need for early identification of CVD risk among breast cancer 
survivors shortly after diagnosis. Furthermore, interventions to reduce CVD mortality may be 
warranted for elderly and ER-positive breast cancer survivors. 
 
Chapter 3: Incident CVD risk factors in women with breast cancer 
 
In chapter 3, we examined whether breast cancer survivors had an increased risk of incident CVD 
risk factors relative to their cancer-free peers in BOSS, a cohort of women with familial risk for 
breast cancer. For this study, we focused on potentially modifiable risk factors that develop 
shortly after diagnosis since we hypothesized that this could be a crucial point of intervention to 




developing high triglycerides relative to their cancer-free peers, and risk of high triglycerides may 
be even higher among overweight/obese survivors. Finally, we found that women diagnosed at 
age ≤50 years may have an over 2-fold higher risk of hypertension compared to cancer-free 
women. Overall, these results suggest that early monitoring of CVD risk factors may be 
warranted. If additional studies confirm our results, clinicians should monitor triglyceride levels 
among all breast cancer survivors, particularly among overweight/obese survivors, and blood 
pressure among breast cancer survivors diagnosed at age ≤50 years. 
 
Chapter 4: Bone loss in women with breast cancer 
 
In chapter 4, we assessed the risk of osteopenia, an early indicator for bone loss, and osteoporosis 
in breast cancer survivors compared to cancer-free women in the BOSS cohort. In this study, we 
observed that young breast cancer survivors had an over 2-fold increased risk of osteopenia and 
osteoporosis relative to their cancer free peers even after accounting for age and menopause, 
which are strong confounders. This suggests that the underlying etiology of excess bone loss in 
breast cancer survivors is likely treatment related. We further observed that women diagnosed at 
age ≤50 years, women with ER-positive tumors, and those treated with AIs or combined 
chemotherapy plus AIs or tamoxifen had a greater risk of osteopenia and osteoporosis compared 
to cancer-free women. These findings emphasize the importance of implementing a baseline 
evaluation of bone density close to breast cancer diagnosis, particularly among young survivors 
being treated with chemotherapy and tamoxifen, and subsequent monitoring so that early steps 







Our findings suggest several future directions for research. First, there are several specific 
questions that follow directly from our results on all-cause mortality in breast cancer survivors. 
These include evaluating the effect of treatment regimes and specific treatment over time on the 
risk of all-cause and cause-specific mortality to clarify how treatment may be driving our results. 
To further explain the observed increasing risk over time in older survivors, the impact of 
prevalent and incident comorbidities on mortality should also be assessed. Larger prospective 
studies with breast cancer survivors and cancer-free women will facilitate examining all of these 
next steps. 
 
Although, we found that CVD-related mortality may manifest several years after diagnosis, 
particularly among survivors diagnosed at an older age or with ER-positive tumors, subsequent 
studies with a larger sample size are needed to confirm these findings. Several questions also 
follow this research. First, identifying specific types of CVD that are most common among these 
survivors (e.g., ischemic heart disease, hypertensive heart disease, or heart failure) and examining 
CVD incidence rather than only CVD-related mortality is needed. If confirmed, research on 
monitoring for early as well as late cardiovascular toxicity in breast cancer survivors is warranted. 
In addition, further research is needed to understand smaller changes in cardiac function in breast 
cancer survivors such as the relationship between hormones and diastolic function. Finally, 
evaluating whether risk of CVD-mortality could be reduced among high-risk groups by 
intervening on certain modifiable factors, such as weight loss, physical activity, healthy diet, and 
preventative medications such as beta-blockers, angiotensin-converting enzyme (ACE) inhibitors, 
statins, and aspirin, is needed.  
 
Although our investigation of incident CVD risk factors shortly after diagnosis was novel, these 
findings need to also be confirmed in larger studies. Since we were limited to a small number of 




hypotheses that specific treatments may play a role in the development of high triglycerides in all 
breast cancer survivors and hypertension among younger breast cancer survivors. Although, we 
observed an increased risk of incident CVD risk factors shortly after diagnosis, risk of developing 
these factors over the long-term and whether these risk factors persist over time needs to be 
evaluated.  
 
Finally, research efforts should be directed to determine more effective approaches to minimize 
bone loss in young breast cancer survivors. Our findings suggest that monitoring bone loss in 
young breast cancer survivors close to diagnosis could prevent the development of osteopenia or 
progression to osteoporosis. However, the optimal frequency of monitoring, particularly by 
specific age and treatment groups, remains unknown. Importantly, bone loss is preventable with 
proper interventions, such as lifestyle and pharmacologic interventions, to preserve bone density 
or treat established osteoporosis (e.g., bisphosphonates or denosumab).3,4  
 
Public health significance 
 
This research contributes novel information on incidence and timing of several short- and long-
term adverse outcomes due to breast cancer and its treatment. First, medical surveillance among 
survivors should further emphasize CVD prevention, particularly among older survivors and 
women with ER-positive tumors. Second, our findings highlight the need for closer monitoring of 
incident CVD risk factors, particularly high triglycerides among all breast cancer survivors and 
hypertension among younger survivors, and implementing interventions shortly after diagnosis to 
reduce CVD burden. Finally, our research highlights the importance of evaluating bone density 
close to diagnosis and implementing subsequent monitoring to reduce the risk of bone loss among 




tamoxifen. Importantly, this research further informs survivorship care guidelines by highlighting 
specific high-risk groups which may require additional screening and monitoring as well as 
interventions to reduce the burden of comorbidities and improve long-term survival. This 
research also informs the design of future cancer survivorship studies, which should incorporate a 
cancer-free comparison, start at time of diagnosis, and include both pre- and post-menopausal 
women. Collectively, these findings support a tailored approach for treatment and prevention 
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